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Summary 
 
 
Plasmocytoma is characterized as a tumor in which all malignant plasma cells exhibit 
identical rearrangement and mutation of immunoglobulin variable genes, and secrete a 
monoclonal immunoglobulin or its fragments (paraprotein). In the course of disease the third 
complementarity-determining region (CDRIII) of this immunoglobulin remains stable,        
i.e. there is no evidence of ongoing somatic hypermutation. Therefore, the idiotype (i.e. the 
unique antigenic structure) of monoclonal immunoglobulin in an individual patient could 
serve as a tumor-specific antigen. However, due to genetic recombination, there are several 
myelomas lacking production of immunogloblin heavy chain but have free monoclonal light 
chains. In these cases of plasmocytoma, a defined tumor-associated antigen is provided by the 
variable region of the corresponding light chain (VLIgPl) in order to elicit a tumor specific 
immune response.  
 
Since plasmocytoma is still an incurable disease despite some recent progress in the 
development of high dose chemotherapy, development of immunotherapy approaches 
designed to get cytotoxic T lymphocytes (CTL) may help to eradicate or control the tumor. 
Aim of this thesis was induction of an in vitroautologous T cell proliferation restricted to 
MHC class I molecules against VLIgPl through autologous dendritic cells (DC) via retroviral 
transduction of human CD34+ progenitor cells.  
 
The cytokine requirements to differentiate CD34+ progenitor cells from different sources into 
DC are known to be different. GM-CSF plus TNF-a ± SCF used in most protocols described 
not only for generation of DC but also of macrophages and neutrophils. Therefore, this work 
provides data that mature DC can differentiate from CD34+ cells of different origins in the 
presence of PMA alone under serum-free conditions without generation of cellular 
intermediates and other lineages. This may facilitate in vitro studies of primed or genetically 
modified DC against infectious and tumor-associated antigens.  
 
Most retroviral vectors contain a bacterial antibiotic-resistance gene such as neomycin that is 
strongly immunogenic. Its peptides will be present d on MHC class I molecules and activate 
CD8+ T lymphocytes, thus skewing the elicited immune response. In order to minimize such 
immune action against xenogenic peptides, a novel retroviral expression-cloning vect r that 
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directs the tumor-associated antigen of plasmocytoma fused in frame with a FLAG antibody-
binding site to the plasma membrane via a glycosylphosphatidylinositol (GPI)-anchor has 
been constructed. Thus, transfected or transduced cells can be detected using monoclonal anti-
FLAG antibodies. PI-PLC releases cell surface FLAG-antigen from transduced CD34+ 
progenitor cells indicating that the retroviral vector targets the fusion protein to the cell 
surface via GPI-anchor. VLIgPl transgene expression in DC using the novel retroviral vector 
elicited a strong autologous T cell proliferation restricted to MHC class I molecules. This 
proliferative response is more prominent in PMA-derived DC compared to cytokine-deriv d 
DC indicating that PMA-derived DC are more potent in activating autologous T cell 
proliferation. In addition, T cell proliferation could be inhibited almost completely by CD86 
antibodies.  
 
It can be concluded from these data that autologous T cells could recognize immune epitopes 
within the myeloma VLIg, which had been presented by DCon MHC class I molecules. In 
addition, CD86 co-stimulatory molecule plays a critical role in activation of naive T cells. 
This result will aid in the generation of VLIg-based immunotherapy in multiple myeloma. 
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Zusammenfassung 
 
 
Das multiple Myelom ist gekennzeichnet durch eine identische Rekombination und 
Hypermutation der variablen Regionen im Bereich der Immunglobulingenloci in allen 
neoplastischen Plasmazellen. Somit produzieren die Tumorzellen ein monoklonales 
Immunglobulin oder seine Fragmente (Paraprotein). Daher kann der Idiotyp, die einzigartige 
antigene Struktur, des monoklonalen Immunglobulins bei Myelompatienten als Tumor-
spezifisches Antigen dienen. Aufgrund einer genetischen Rekombination kommt es bei 
einigen Patienten bzw. in einigen Myelomzellen zu einem Fehlen der schweren Kette des 
Immunglobulins, diese Zellen jedoch produzieren freie monoklonale Leichtketten. Bei diesen 
Myelompatienten steht die variable Region der korrespondierenden Leichtkette (VLIgPl) als 
spezifisches Antigen zur Induktion einer Tumor-spezifischen Immunantwort zur Verfügung. 
 
Trotz einigen Fortschritts und der Entwicklung der Hochdosis-Chemotherapie bleibt das 
multiple Myelom eine unheilbare Erkrankung. Daher sollen Immuntherapien entwickelt 
werden, um zytotoxische T-Lymphozyten zu generieren, die zur Eradikation des Tumors 
beitragen sollen. Ziel dieser Doktorarbeit war, die Induktion einer in vitro-autologen T-Zell-
Proliferation zu etablieren, als eine MHC Klasse I restringierte, gegen VLI Pl gerichtete 
Antwort gegen autologe DC nach retroviraler Transduktion von CD34+ Progenitorzellen. 
  
Die Zytokinzusammensetzung, um CD34+ Zellen zu differenzieren unterscheiden sich 
bekanntlicherweise in Abhängigkeit von der Herkunft der CD34+ Zellen. GM-CSF und    
TNF-a ± SCF werden in den meisten Protokollen verwendet, dabei differenzieren aber nicht 
nur DC sondern auch Makrophagen und Neutrophile. In dieser Arbeit wurden DC aus CD34+ 
Zellen verschiedenen Ursprungs durch Stimulation mit PMA in serumfreien Medien ohne die 
Bildung von Intermediärstadien und anderen Differenzierungslinien generiert. Dieses 
Ergebnis könnte in vitro-Studien ermöglichen unter Verwendung von Antigen-gepulst  oder 
genetisch modifizierten DC gegen infektiöse oder Tumor-assoziierte Antigene. 
 
Die meisten retroviralen Vektoren enthalten ein bakterielles Antibiotika-Resis enzgen wie 
Neomycin-Resistenzgen, das stark immunogen wirkt. Seine Peptide könnten auf MHC  
Klasse I Molekülen präsentiert werden und dadurch CD8+ T-Lymphozyten aktivieren, 
wodurch es zu einer Verschiebung der Immunantwort kommt. Um solche Immunantwort 
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gegen xenogene Peptide zu minimieren, ist einen neuartigen retroviralen Expressionsvektor 
konstruiert worden, der zu einer Expression des Tumorantigens ohne Rasterverschiebung mit 
einer FLAG-Antikörperbindungsstelle als Glycosylphosphatidylinositol (GPI)-verankertes 
Peptid führt. Transfizierte bzw. transduzierte Zellen können somit durch monoklonale anti-
FLAG Antikörper nachgewiesen werden. PI-PLC führt zu einer Ablösung des FLAG-
Antigens von der Oberfläche der transduzierten Progenitorzellen. VLIgPl-Transgenexpression 
in DC durch den retroviralen Vektor führt zu einer starken autologen T-Zellpr lif ration, die 
MHC Klasse I restringiert ist. Die T-Z llproliferation konnte nahezu vollständig durch CD86 
monoklonale Antikörper gehemmt werden. Diese proliferative Antwort ist unter Verwendung 
von PMA-differenzierten DC im Vergleich zu Zytokin-differenzierten DC deutlich 
ausgeprägter, wodurch gefolgert werden kann, daß die PMA-differ nzierten im Vergleich zu 
den Zytokin-differenzierten DC in der Induktion einer autologen T-Zellantwort eine deutlich 
stärkere Potenz aufweisen.  
 
Aus diesen Daten kann geschlossen werden, daß autologe T-Zellen immunogen Epitope 
innerhalb des Myelom VLIg erkennen können, die durch DC auf MHC Klasse I Molekülen 
präsentiert werden. Außerdem spielt das CD86 kostimuluierende Molekül eine entscheidende 
Rolle in der Aktivierung naiver T-Zellen. Diese Ergebnisse könnten eine Grundlage bilden 
zur Etablierung einer VLIgPl-basierten Immuntherapie beim multiplen Myelom. 
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1  Introduction 
 
 
1.1  Paraprotein 
 
A secreted monoclonal immunoglobulin (Ig) molecule or its fragment (free heavy or light 
chain) accumulating in plasma is called a paraprotein. A secreted molar surplus of its light 
chain, escaping through the glomerular filter and appearing in urine, is called Bence Jones 
protein (Stevenson, 1998). Paraproteins and Bence Jones proteins are normally detected on 
protein electrophoresis of serum or urine, respectively, as a dense narrow band of g-mobility 
(Figure 1). The presence of a paraprotein implies a monoclonal proliferation of Ig-secreting   
B cells or plasma cells, which can be premalignant or malignant (Samso , 2000). 
 
 
 
Figure 1: Multiple myeloma serum electrophoresis shows a notable narrow "spike" of 
monoclonal immunoglobulins (paraproteins) of g-mobility. Electrophoresis using urine 
samples can also detect Bence Jones proteins. EP: electrophoresis, M: monoclonal 
immunoglobulin (from Multiple Myeloma Research Foundation, MMRF). 
 
 
Diseases associated with paraproteins  
 
Diseases associated with paraproteins are classified into plasma cell malignancies, B cell 
lymphoid malignancies (including Waldenstrom´s macroglobulinaemia), monoclonal 
gammopathy of undetermined significance (MGUS) and primary amyloidosis. Plasma cell 
malignancies include multiple myeloma, solitary plasmocytoma of bone and extramedullary 
plasmocytoma. Waldenstrom´s macroglobulinaemia is a malignancy of IgM secreting 
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lymphoplasmacytoid cells, associated with lymphadenopathy and splenomegaly as well as 
marrow involvement. Other B cell tumors including chronic lymphocytic leukaemia and hairy 
cell leukaemia are sometimes associated with the presence of a paraprotein. MGUS is a 
disorder in which a paraprotein is present with no other features to suggest a diagnosis of 
myeloma or other B cell malignancy. Although some cases remain stable for many years, 
approximately 1 % cases transform to overt multiple myeloma every year. More rarely 
transformation to another B cell malignancy may occur. Primary amyloidosis is a condition in 
which a paraprotein is produced whose particular characteristics lead to deposition of 
fragments of immunoglobulin light chains as amyloid fibrils within tissues. Approximately  
10 % of patients with myeloma will develop primary amyloid and rare cases are associated 
with Waldenstrom´s macroglobulinaemia and other B cell tumors (Samson, 2000). 
 
 
1.2  Multiple myeloma 
 
Multiple Myeloma (MM) is a tumor of plasma cells, occurring usually within the bone 
marrow but sometimes at other body sites. Neoplastic cells form discrete nodules, which 
erode the surrounding bone. All malignant plasma cells in plasmocytoma show identical 
rearrangements and mutations of immunoglobulin variable genes and secrete a monoclonal 
(identical) immunoglobulin (Ig) or its fragments. In the course of disease the third 
complementarity-determining region (CDRIII) of this immunoglobulin remain stable (Sahota 
et al., 1997; Kosmas et al., 1999), i.e., there is no evidence of ong ing somatic hypermutation 
(Ludwig et al., 1999). The idiotype (i.e. the unique antigenic structure) of monoclonal 
immunoglobulin in an individual patient can be a tumor-specific antigen (Bataille and 
Harousseau, 1997). However, due to genetic recombination, there are several myelomas 
lacking production of immunogloblin heavy chain but have free monoclonal light chains 
(Sakai et al., 1993). Therefore, in these cases of plasmocytoma, a defined tumor-associa ed 
antigen is provided by the variable region of the corresponding light chain (VLIgPl) in order 
to elicit a tumor specific immune response.  
 
In about 75 % of cases there is an obvious plasma paraprotein (in order of frequency IgG, 
IgA, IgD or IgE), in about 50 % a Bence Jones protein excretion exceeding 500 mg day-1 and 
in perhaps 10 % a clinically significant light-cha n amyloidosis, associated with tissue 
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deposition of the tumor light chains or fragments thereof (Stevens n, 1998). Occasionally     
(< 1 %) myeloma is "non-secretory" and produces no monoclonal immunoglobulin.  
 
Nonetheless the disease can remain asymptomatic for many years. In the symptomatic phase 
the most common presenting complaint is bone pain (Durie, 1996). The clinical 
manifestations are diverse but often include paraproteinemia, osteolytic lesions, impairment 
of renal function and hyporegenerative bone marrow (Di op ulos et al., 1995; Clark et al., 
1999).  
 
 
1.2.1  Incidence 
 
Multiple myeloma accounts for approximately 1 % of all cancers and 10 % of hematological 
malignancies (Chiriva-Internati et al., 2001). It is considered as a disease of older adults, 
presenting most commonly in individuals aged over 50 years, with a median age of 70 in 
women and 68 in men (Huang et al., 1999). The incidence of myeloma is 3-4/100,000 in the 
USA. This leads to approximately 13,500 new cases of myeloma in the USA each year. 
Myeloma is more common in blacks than whites. The incidence varies from country to 
country around the world from a low of 1/100,000 in China to approximately 4/100,000 in 
most Western industrialized countries. The male/female ratio is 3:2. The incidence rises with 
age. Better diagnostic techniques and the higher average age of the general population may 
explain the rising incidence over the last decades. However, a trend towards more frequent 
myeloma in patients under age 55 implies important environmental causative factors in the 
past 3-4 decades (Durie, 1996). 
 
 
1.2.2  Pathophysiology 
 
Multiple myeloma is now known to arise from a post germinal center B cell in the lymph 
node which homes to the bone marrow. Interactions with stromal cells in the marrow facilitate 
homing and growth of the myeloma cells. The expression of adhesion molecules such as 
NCAM (CD56), syndecan 1 (CD138) and PECAM 1 (CD31) on myeloma plasma cells is 
thought to facilitate homing to the marrow (V n Riet et al., 1998). In addition, neoplastic 
plasma cells have been found to express high levels of the IL-6 receptor (Foxwell et al., 
1998). The stromal cells produce IL-6, which is an important growth factor for myeloma cells, 
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while myeloma cells produce factors such as TNF-a and IL-1b that activate osteoclasts, 
resulting in myeloma bone disease. These cytokines also stimulate the stromal cells to 
produce IL-6. Myeloma cells also produce vascular endothelial growth factor, which results in 
increased microvessel formation in the marrow promoting tumor growth (Samson, 2000).  
 
Researchers have found that excess IL-6 production may result from infection with Kaposi's 
sarcoma- ssociated herpesvirus (KSHV) also called human herpesvirus-8 (HHV-8). This 
virus has been found in the blood of most patients with myeloma. The viral genome codes for 
production of a number of viral homologues of proteins involved in cell proliferation and cell 
death including a vIL-6 homologue. In view of the role of IL-6 in myeloma growth it seem  
possible that HHV-8 might also play a role in the pathogenesis of myeloma. This discovery 
needs to be confirmed in additional studies but, if true, represents an important advance in 
understanding (and possibly, treating or preventing) this cancer (Samson, 2000).  
 
Recent studies have found that abnormalities of some oncogenes (such as c-myc) develop 
early in the course of plasma cell tumors. Changes in other oncogenes (such as N-ras and    
K-ras) are more often found in myeloma after bone marrow relapse and changes in tumor 
suppressor genes (such as p53) are associated with spread to other organs (Durie, 1996; 
Bataille and Harousseau, 1997). Table 1 shows chromosomal aberration in multiple myeloma 
(Ludwig et al., 1999). Deletions of tumor suppressor genes (such as p53), partial or total loss 
of chromosome 13 and rearrangements of ba d 14q32 (the immunoglobulin heavy-c ain 
locus) and 11q13 are frequently found in multiple myeloma, and were shown to harbour 
prognostic significance. These cytogenetic abnormalities appear to make the myeloma more 
aggressive and resistant to treatment (Ludwig et al., 1999; Drach et al., 2000). Deletions of 
p53 and retinoblastoma (Rb)-gene lead to disruption of cell cycle control. Furthermore, loss of 
these tumor-suppressor genes may lead to increase autocrine secretion of IL-6 by tumor cells, 
since the p53 and Rb-gene products normally repress the IL-6 promoter (Santhanam et al., 
1991). In multiple myeloma, p53 aberrations do not seem to be the initiating event 
(Ackermann et al., 1998). However, IgH translocations may be a nearly universal and 
possibly early event in multiple myeloma (Hallek et al., 1998). The chromosomal aberration 
was proposed as novel prognostic factor, since survival time was only 13.9 months from 
diagnosis for patients with a deletion of the p53 gene versus 38.7 months for patients with 
absence of this abnormality (Drach et al., 1998). Deletion of Rb (13q12) or monosomy 13 
was associated with a median survival of 10 months in patients receiving standard treatment 
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versus 34 months for patients with other abnormalities (Seong et al., 1998). In addition, 
patients with an unfavorable karyotype had a median overall survival of 26 months versus  
69+ months for patients with an abnormal karyotype but absence of translocation, deletion of 
Rb or 11q abnormalities (Ludwig et al., 1999).    
 
Oncogene/tumor suppressor gene Chromosomal aberration Frequency (%) 
retinoblastoma (Rb) del 13q12 50 % 
ras-mutations - 34 % 
p53 del 17p13 33 % 
FGFR3 t (4; 14)(p16; q32) 25 % 
bcl-1/cyclin D1 t (11; 14)(q13; q32) 20 % 
bcl-2 t (14; 18)(q32; q21) < 5 % 
c-myc t (8; 14)(q24; q32) < 5 % 
 
Table 1: Molecular mechanisms of malignant transformation in multiple myeloma (Ludwig   
et al., 1999). 
 
Uncontrolled growth of plasma cells has a large range of consequences including bone 
marrow failure, increased plasma viscosity, suppression of normal immunoglobulin 
production, skeleton destruction and renal insufficiency. The characteristic sharply 
demarcated bone defects are due to osteoclast activation by TNF-  a d IL-1b released by 
tumor cells. X-rays may show lytic lesions and generalized osteoporosis is also common. 
Vertebral collapse is frequent in myeloma patients, leading to back pain, kyphosis and loss of 
height and occasionally resulting in cord compression. Pathological fracture of a long bone 
may also occur. The bone destruction may result in hypercalcaemia, although serum alkaline 
phosphatase is usually normal since bone alkaline phosphatase reflects osteoblast activity and 
in myeloma osteoblast activity is reduced (Samson, 2000). 25-30 % of patients have some 
degree of renal impairment and about 5 % will present with acute renal failure. This is most 
commonly due to Bence-Jon s protein, which damages the tubules as it passes through the 
kidney. The classic histological features are of fr ctured distal tubular casts with a 
surrounding chronic inflammatory infiltrate including giant cells (myeloma kidney). Much 
less frequently light-c ain deposition may produce a form of glomerulopathy (light-chain
amyloidosis). Other factors that can contribute to renal failure include hypercalcaemia, 
infection, dehydration, hyperuricaemia and amyloid deposition. Renal failure, which results 
acutely from hypercalcaemia or dehydration, is often reversible with appropriate management 
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but that due to Bence-Jon s protein is less likely to recover (Samson, 2000). Anaemia is 
another common presenting future and appears to be mediated by cytokines such as IL-1b 
rather than being directly due to marrow replacement. In some patients renal failure may also 
contribute to the anaemia (Samson, 2000). About 10 % of myeloma patients develop primary 
amyloidosis. Kidneys usually are affected with deposition of amyloid in the glomeruli leading 
to generalized proteinuria and nephrotic syndrome. Peripheral neuropathy (particularly carpal 
tunnel syndrome), congestive cardiac failure and involvement of skin, muscle and join may 
also occur. Peripheral neuropathy may also occur in myeloma patients even without 
amyloidosis. Very high Immunoglobulin (Ig) particularly of IgA may result in hyperviscosity 
syndrome, with headaches, visual disturbance and loss of concentration (Samson, 2000). 
Increased bleeding is often accentuated by thrombocytopenia, in addition to the binding of 
monoclonal proteins to clotting factors and/or platelets (Durie, 1996). There is impairment of 
both humoral and cell-mediated immunity due to neutropenia and decreased production of 
polyclonal immunoglobulins leading to an increased susceptibility to infection, both bacterial 
and viral. Although pneumococcal pneumonia is one of the "classical" infections associated 
with myeloma, other bacteria such as streptococci and staphylococci are now frequently 
isolated. Also, Haemophilus and Herpes zoster infections are often seen (Durie, 1996).  
 
 
1.2.3  Newer treatment strategies 
 
Myeloma is still an incurable disease. Using standard chemotherapy, complete remission rates 
have not exceeded 5 % and the median survival has not been extended byond 3 years 
(Alexanian and Dimopoulos, 1994). High-dose chemotherapy or chemo-radiotherapy with 
haematopoietic stem cell support would be an alternative to extend event-free a  o rall 
survival and to increase the complete response rate after therapy (Attal et al., 1996; Barlogie 
et al., 1997). However, relapse is still a major cause of treatment failure (Peest et al., 1995; 
Tricot et al., 1995). Therefore, novel alternative therapeutic strategies are much needed in 
these patients (Lim and Bailey-Wood, 1999; Wen et al., 2001). The development of 
immunotherapy approaches designed to get cytotoxic T lymphocytes (CTL) may help to 
eradicate or control residual tumor cells (Tart  et al., 1999). The use of professional antigen-
presenting cells (APC) such as dendritic cells (DC) to generate anti-tumor response is a 
promising strategy (Hart, 1997; Schuler and Steinman, 1997). Vaccination of patients with 
DC pulsed with monoclonal Ig as tumor antigen (Ag), tumor RNA or cell lysates have already 
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begun in MM (Lim and Bailey-Wood, 1999; Reichardt et al., 1999; Hajek and Butch, 2000; 
Timmerman and Levy, 2000; Titzer et al., 2000). 
 
 
1.3  Dendritic cells 
 
Dendritic cells (DC) are found at trace levels in tissues or in circulation and are inducing 
many lymphocyte functions (Banchereau et al., 2000). During the past decade, DC have been 
identified as the most potent APC of the immune system (Cella e  al., 1997; Rughetti e  al., 
2000), which play a key role in generating primary and probably secondary immune 
responses against specific antigens. Dendritic cells have unique migratory properties (Aust n, 
1996) and the capacity to acquire, process and then present antigens in association with the 
appropriate accessory signals to T lymphocytes (Steinman, 1991; Hart, 1997). The role DC 
play in the body’s natural immune response has become an important question. The increased 
tumor incidence in immunosuppressed patients implies that the immune system controls 
tumor evolution and several studies have suggested that greater numbers of DC within a 
tumor lead to a better prognosis. However, the existence of a malignant tumor and its 
inevitable progression without treatment demonstrate the ability of tumors to escape DC-
mediated immune surveillance (Troy and Hart, 1997).  
 
The superior ability of DC to present antigens to T cells has led to the development of DC-
based strategies for the purpose of enhancing the immune response against tumors and 
infectious agents (Banchereau et al., 2000; Kirk and Mule, 2000). A growing number of 
tumor-associated antigens (TAA) have been identified that are recognized by T lymphocytes 
and are capable of provoking an anti-tumor immune response (Boon et al., 1994).  Dendritic 
cells have now been shown to be effective in stimulating TAA-specific T lymphocyte 
responses in vitro. These results and significant DC-induced responses in animal models have 
encouraged the first clinical attempts (Hsu et al., 1996; Murphy et al., 1996; Nestle et al., 
1998) to exploit DC for cellular immunotherapy against cancer. However, the application of 
DC in immunotherapy has been hampered by the low number of these cells and the difficulty 
of isolating them (Heemskerk et al., 1999).  
 
Mature DC are typically characterized by expression of MHC class I, MHC class II, the co-
stimulatory molecules CD80 (B7-1) and CD86 (B7-2) and the dendritic cell lineage marker 
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CD83 (Hart, 1997). The identification of culture conditions enabling the generation of mature 
DC in vitro is useful to study their biology and to prepare large amounts of APC for 
immunotherapeutic purposes (Ferlazzo et al., 1999).  
 
 
1.3.1  In vitro generation of DC 
 
It is now possible to generate a large number of DC in vitro from either peripheral blood 
monocytes (Kiertscher and Roth, 1996; Zhou and Tedder, 1996) o  from CD34+ progenitor 
cells in cord blood [CB] (Santiago-Schwarz et al., 1992; Sato et al., 1998), bone marrow 
[BM] (Reid et al., 1992; Szabolcs et al., 1995) and peripheral blood [PB] after cytokine 
mobilization (Strunk et al., 1996; Ratta et al., 1998). CD34-derived dendritic cells (CD34-
DC) have a preferential capacity to activate CD8+ T cells (Ferlazzo et al., 1999). These 
methods used different cytokine-cocktails to stimulate in vitro growth and differentiation and, 
although time consuming, have the capacity to generate expanded DC numbers (Troy a d 
Hart, 1997). Because cytokine receptor stimulation activates complex signalling cascades that 
initiate multiple responses, differentiation to other lineages is almost simultaneously induced. 
Thus cytokine application not only generates DC but also macrophages and neutrophils as 
well (Santiago-Schwarz et al., 1992; Szabolcs et al., 1995; Bender et al., 1996). In addition, 
FCS was used as culture supplement in most protocols described. There are many problems 
with using serum-replete medium to generate DC such as variation in the cytokine content of 
serum, imunogenicity of animal proteins and the risk of infectious agents. Recently, serum-
free culture conditions have been described for generation of cord blood-derive  dendritic 
cells (CB-DC) in the presence of SCF, GM-CSF, TNF-a and TGF-b1 (Bello-Fernandez et al., 
1997). In addition, DC can be generated from mobilized peripheral blood CD34+ cells in the 
absence of bovine products using X-Vivo 10 culture medium containing 10 % autologous 
serum, rhGM-CSF, rhTNF-a and rhIL-4 (Ardeshna et al., 2000a).  
 
 
1.3.2  Antigen processing and presentation by DC  
 
Antigen processing has been described traditionally as occurring through one of the two 
distinct pathways identified for endogenous and exogenous antigens. Endogenously derived 
antigenic peptides bind with transporter (TAP) gene products in the cytosol and are delivered 
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to the MHC class I compartment in the endoplasmic reticulum for incorporation into the 
peptide-binding groove of the MHC molecule. These MHC class I / peptide complexes are 
then transported to the cell surface, where they are recognized by CD8+ cytotoxic                     
T lymphocytes (CTL) (Lanzavecchia, 1996). Exogenous antigens enter the DC via 
endocytosis, phagocytosis or macropinocytosis (Wa ts, 1997) and are degraded in low pH 
endosomal compartments into peptide fragments that then complex with class II MHC 
molecules for surface presentation to CD4+ T helper (Th) cells (Kleijmeer et al., 1995; 
Nijman et al., 195). It has become apparent that this classic dichotomy between exogenous 
(MHC II restricted) and endogenous (MHC I restricted) antigen presentation does not account 
for all antigen processing, particularly in DC. Additional mechanisms have been identified 
whereby exogenously acquired antigens are processed and presented on MHC class I 
molecules (Watts, 1997). Thus, antigens taken up by macropinocytosis can be released as 
peptides to bind with TAP proteins in the cytosol for delivery to the MHC class I 
compartment (Norbury et al., 1997). Alternatively, peptides when present in high 
concentrations may externally exchange with peptides on surface MHC molecules, thus 
bypassing intracellular processing. Endogenous antigens (ofte  autologous) can also enter the 
MHC class II pathway and generate significant CD4+ responses (Lechler et al., 1996). 
However, for therapeutic applications the binding affinity and stimulatory activity of each 
such tumor derived peptide needs to be characterized. 
 
 
1.3.3  Co-stimulatory molecules of DC 
 
In addition to presenting MHC/Peptide antigen complexes, DC must (as APC) provide 
essential accessory signals to T lymphocytes. This requires intimate cellular contact between 
DC and T lymphocytes. Expression of one or both of the co-stimulator molecules B7-1 
(CD80) and B7-2 (CD86) on APC are essential for effective activation of naive                      
T lymphocytes (Guinan et al., 1994). These co-stimulatory molecules bind to CD28 molecule 
on T lymphocytes. If this fails to occur at the time of antigen recognition by the T cell 
receptor, a different T lymphocyte function such as anergy results (Guinan et al., 1994; 
Schwartz, 1996). CD86 is the most important ligand to induce CD28-mediated co-stimulation 
for CD8+ T cell activation (Van Gool et al., 1999). On naive T cells, CD28 is the only 
receptor for B7 molecules. Once  T cells are activated, however, they express an additional 
receptor called CTLA-4 (CD152). CTLA-4 closely resembles CD28 in sequence and the two 
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molecules are encoded by closely linked genes. CTLA-4 binds B7 molecules about 20 times 
more avidly than CD28 and delivers an inhibitory signal to the activated T cell. This makes 
the activated progeny of a naive T cell less sensitive to stimulation by the antigen-presenting 
cell and limits the amount of the T cell growth factor IL-2 pr duced. Thus, binding of   
CTLA-4 to B7 molecules is essential for limiting the proliferative response of activated         
T cells to antigen and B7 on the surface of antigen-presenti g cells (Gribben et al., 1995, 
1996; Rudd, 1996). This was confirmed by producing mice with a disrupted CTLA-4 gene. 
Such mice develop a fatal disorder characterized by massive proliferation of lymphocytes 
(Tivol et al., 1995). Other DC surface molecules, including CD40, probably contribute to      
T lymphocyte activation (McLellan et al., 1996) and it is possible that te DC co-stimulatory 
molecule repertoire, which may include other surface molecules, partially defines the type of 
T lymphocyte response resulting. For example, CD80 and CD86 may generate Th1- and    
Th2-based response, respectively (Kuchro et al., 1995). Dendritic cells also produce 
cytokines, such as IL-12 (Heufler et al., 1996) and IL-7 (Mehrotra et al., 1995), which 
contribute to T cell activation and CTL differentiation. Other APC, such as B cells and 
macrophages, are also effective stimulators of primed T lymphocytes but the DC is special in 
its ability to stimulate naive T lymphocytes and hence, it is predicted to be critical in driving 
any initial response against TAA. Finally, a notable feature of DC relevant to their therapeutic 
use is that their ability to take up and process antigen declines as they become 
differentiated/activated into co-s imulatory cells (Troy and Hart, 1997). 
 
 
1.3.4  The effect of malignancy on DC function 
 
In a clinical study on DC within renal cell carcinoma, DC represented only a small proportion 
of the infiltrating leukocytes. Of these, only a small subset of DC was found to display an 
activated phenotype. These activated DC, when isolated, proved to be significantly stronger 
stimulators of T lymphocytes than either the inactivated DC or the tumor macrophages. These 
findings suggest that the tumor environment inhibits DC maturation and activation, providing 
a possible explanation for the paradox that antigen-expressing tumor cells can be recognized 
by T lymphocytes in vitro yet escape tumor surveillance and grow into lethal tumors in 
immunocompetent hosts (Troy and Hart, 1997).  
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Potential mechanisms for the defects in APC function with the result of T cell anergy 
observed in tumor-bearing hosts have been identified recently. Vascular endothelial growth 
factor, which is produced by most solid tumors, has been identified as directly responsible for 
inhibiting maturation of DC from precursor cells (Gabrilovich et al., 1996a). IL-10, also 
produced by many tumors (Sato et al., 1996), inhibits up-regulation of CD80/CD86 co-
stimulatory molecules on APC (Willems et al., 1994), and their expression is essential for 
effective DC-T lymphocyte interaction. Activation of T lymphocytes by APC, in the presence 
of IL-10, leads to long-term anergy in the T lymphocytes (Groux et al., 1996). Transforming 
growth factor-b (TGF-b) has also been shown to indirectly inhibit the activation of                 
T lymphocytes by DC (Lipscomb et al., 1993; Summers t al., 1999).  
 
The effects of malignancy on DC function may not be confined to the tumor. A study in mice 
found that mature blood DC from tumor-bearing animals were ineffective at inducing       
anti-tumor CTL (Gabrilovich et al., 1996b), whereas DC generated from BM precursors 
remained fully functional. Tumor cell supernatants did not affect the function of mature DC 
obtained from the spleen of tumor-bearing animals, but significantly suppressed the ability to 
generate functional DC from the bone marrow of control mice in vitro. This suggests that 
tumor cells may release factors, which block early stages of DC maturation from precursors 
(Gabrilovich et al., 1996b). Breast cancer patients have also been suggested to have lower 
numbers of mature DC and these cells showed reduced ability to stimulate autologous and 
allogeneic mixed lymphocyte reactions (MLRs). However, the cytokine-ge rated DC 
derived from circulating precursors were again fully functional (Gabril vich et al., 1997). 
Cytokine-generated DC from patients with renal cell carcinoma (Radmayr et al., 1995) and 
prostate cancer have also been shown to be fully functional (Tjoa e  al., 1995). Routine DC 
counting is now being applied to a range of patients, including cancer patients (Troy and Hart, 
1997).  
 
 
1.3.5  DC as cellular immunotherapy  
 
There are now multiple methods for providing DC with antigens to process and present 
(Shurin, 1996). Initial studies used extracts from tumor cell lysates with variable degree of 
purification. This method avoids the restriction of a define TAA but clearly increases the 
theoretical risk of immunizing against self-an ig ns (Troy and Hart, 1997). Purified proteins, 
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stripped tumor cells peptides (Zitvogel et al., 1996) and synthetic peptides (Shurin, 1996) 
permit a more specific immunization. Presentation of TAA by these methods may be limited 
by turnover of MHC complexes, but DC retain antigen for prolonged periods and migrate 
relatively quickly to draining lymph nodes (Barratt-Boyes et al., 1997). Longer lasting 
presentation of antigen may be obtained by DNA-based expression within the DC, but 
whether this is more effective remains to be established (Troy and Hart, 1997). This has been 
achieved by either transduction with specific cDNA (Condon et al., 1996) or the 
establishment of DC/tumor cell chimeras using cell fusion techniques (Gong et al., 1997). 
Introducing genes into DC by retroviral transduction of CD34+ progenitor cells is now an 
established method to potentiate specific immune response against tumor antigens (Reeves    
et al., 1996). 
 
 
1.4  Retroviral vectors 
 
1.4.1  Basics of retrovirus biology 
 
Retroviruses have been widely employed as v ctor systems because they can permanently 
express a foreign gene into mitotic cells. Moreover, they can infect virtually every type of 
mammalian cell, making them exceptionally versatile. Th  virus itself is surrounded by a 
phospholipid membrane, derived from the host cell from which it has arisen (Figure 2). 
Imbedded in the membrane are several different glycoproteins, involved in host cell 
recognition and facilitating virus-cell fusion events. Within this membrane envelope there is a 
protein capsid containing genetic material for the virus. Retroviruses contain 2 identical 
single-stranded RNA genomes, and are prepackaged with proteins enabling the virus to insert 
DNA into the host cell genome. The capsid contains reverse transcriptase, which enables the 
virus to convert its RNA into DNA and integrase, which helps facilitate the insertion of this 
viral DNA into the host's genome. The viral genome is then maintained within the cells as it 
undergoes normal processes, and remains in this fashion even as t e virus becomes active and 
replicates itself (Smith, 1995). 
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Figure 2: Retroviral structure (Smith, 1995). 
 
 
 
 
Figure 3: Retroviral replication cycle (Buchschacher and Wong-Staal, 2000). 
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1.4.1.1  Replication cycle of retroviruses 
 
Basic features of a generic retroviral replication cycle are shown in Figure 3. I fection begins 
when the virus envelope glycoprotein binds to specific receptors located on the cell surface, 
followed by fusion of the viral envelope and cell membrane and release of the virus core into 
the cytoplasm. Viral RNA is uncoated, copied into a double-stranded DNA molecule and 
transported to the nucleus during cell division. Although they are shown in the diagram as 
occurring in a stepwise manner, the exact timing and mechanism of these events are unclear. 
Integration into chromosomal DNA enables the viral genome to be stably maintained, 
replicated during DNA synthesis and passed to progeny cells. This feature makes r troviral 
vectors useful for permanently introducing foreign genes into cells. V ral RNA is produced 
and translated to produce viral proteins and enzymes. Viral RNA also associates with viral 
proteins to form new core particles. Mature progeny virions capable of infecting new cells are 
formed when the cores obtain their envelopes, consisting of cellular membrane and envelope 
glycoprotein, when they are released from the cell (Buchs hacher and Wong-Staal, 2000). 
 
1.4.1.2  Genome structure of retroviruses 
 
The retroviral genome varies in complexity between the different viruses in this family. A 
generic retrovirus, however, contains only three genes (Figure 4). Env encodes the 
glycoprotiens expressed in the viral envelope, pol encodes revers  transciptase and gag
encodes the capsid proteins. Surrounding these genes are LTR's (long terminal repeats), which 
contains regulatory sequences, and sequences that are important as the genome inserts itself 
(Smith, 1995). 
 
 
 
Figure 4: General genome structure of retroviruses (Smith, 1995). 
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1.4.2  Retroviral vector systems 
 
Retroviral vectors are virus derivatives typically engineered to be replication defective. They 
are capable of inecting and integrating a foreign gene into a target cell but are unable to 
multiply and spread to other cells. Vectors are created by removing viral genes from a virus 
genome, leaving only the cis-acting sequences (regions recognized by viral proteins) 
necessary for a single round of replication. A diagram of the architecture of a "typical" 
oncoretroviral vector is shown in Figure 5. As illustrated, all viral genes are removed and 
replaced with either a marker gene (for example, a gene that confers drug resistance) used to 
monitor the vector infection of cells or another foreign gene of interest. More complex vectors 
capable of expressing two or more foreign genes through additional heterologous, internal 
viral promoters or internal ribosome entry site sequences have been designed. Figure 5 shows 
cis-acting sequences that must be present on the vector for propagation to take place. These 
sites are used during various stages of virus replication including reverse transcription of 
genomic RNA [LTR, primer binding site (pbs), polypurine tract (ppt)], integration of the viral 
DNA into chromosomal DNA (att sites), transcription of the provirus (LTR) and packaging of 
viral RNA into progeny virions (encapsidation site) (Buchschacher and Wong-Staal, 2000; Hu 
and Pathak, 2000). 
 
 
 
Figure 5: cis-Acting elements of a typical retroviral vector (Buchschacher and Wong-Staal, 
2000). 
 
Constructs containing these cis-acting sequences can be propagated in cultured cells and can 
therefore serve as vectors when gag, pol and env gene products are provided in trans 
(expressed from other constructs). This trans-complementation can be accomplished in a 
number of ways. Vector and wild-type virus DNA plasmid constructs can be cotransfected 
(introduced by chemical or electrical means) into cells in culture. When vector and wild-type 
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virus (also called "helper virus" because it assists in vector propagation) constructs are 
contained within a single cell, the gene products provided by the replication-competent virus 
result in the production of virus particles containing the vector RNA genome. These virions 
can then infect and introduce the vector genome into other cells. The fact that replicating 
wild-type virus is present prevents the study of a single viral replication cycle and obviously 
would be unacceptable for clinical use (Buchschacher and Wong-Staal, 2000; Hu and Pathak, 
2000).  
 
Techniques capable of propagating vectors without using wild-type virus have been 
developed. Cotransfection of a vector DNA construct and a plasmid expressing viral gene 
products (but not c ntaining cis-acting sequences necessary for propagation) results n a single 
cycle of vector propagation. Because the construct(s) expressing viral proteins do not contain
sequences necessary for replication, helper virus is not produced. After virions containing the 
vector genome are harvested from cotransfected cells and are used to infect fresh cells, the 
vector will not be replicating within infected cells because of lack of xpressed viral p oteins 
(Buchschacher and Wong-Staal, 2000; Hu and Pathak, 2000).  
 
The third and probably best method for propagating retroviral vectors involves the use of 
packaging cell lines. There are cell lines that express viral proteins necessary for vector 
propagation. Such cell lines have improved greatly the efficiency by which virus containing 
vector genomes can be produced (Mill r, 1990). Packaging cell lines are made by introducing 
viral genes on plasmids into cells, which are reproduced on each cell division resulting in a 
constant production of viral structural proteins and replication enzymes. After introduction of 
vector genome into these cells, vector particles are produced (Figure 6). Again, helper virus 
should not be produced, and the vector is propagated only over a single replicatio  cycle.  
 
Packaging cell lines are the preferred method to propagate a retroviral vector for two primary 
reasons. First, the process used to generate the virus is generally simpler and more efficient at 
producing a higher titer of vector virus than the cotransfection techniques. Second, the use of 
packaging cells reduces the possibility that wild- ype virus will be regenerated inadvertently 
by recombination between helper and vector sequences during the transfection process; 
therefore, the virus is considered safer for clinical use. Nonetheless, packaging cell lines are 
regularly and rigorously tested for replication-competent retrovirus by using long-term culture 
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to amplify any regenerated wild-type virus, thus increasing the sensitivity of detection 
(Buchschacher and Wong-Staal, 2000; Hu and Pathak, 2000).
 
 
 
Figure 6: Retroviral packaging cell line and viral vector production (Buchschacher and 
Wong-Staal, 2000). 
 
 
1.4.3  Progress with retroviral vectors 
 
Retroviral vectors are one of the most promising systems for the transfer and the expression of 
therapeutic genes in human gene therapy protocols. Compared with other gene transfer 
systems, retroviral vectors have several advantages, including their ability to transduce a 
variety of cell types, to integrate efficiently into the genomic DNA of the recipient cells and to 
express the transduced gene at high levels. The design of different types o  packaging cells 
has evolved to reduce the possibility of helper virus production. The host range of retroviruses 
has been expanded by pseudotyping the vectors with heterologous viral glycoproteins and 
receptor-specific ligands (Palu et al., 2000). 
 
 
1.5  Aim of work 
 
Since myeloma is still an incurable disease despite some recent progress in the development 
of high dose chemotherapy, novel alternative therapeutic strategies are much needed in these 
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patients. The development of immunotherapy approaches designed to get cytotoxic                
T lymphocytes (CTL) may help to eradicate or control residual tumor cells. The use of 
professional APC such as dendritic cells (DC) to generate anti-tumor response is a promising 
strategy.  
 
Aim of this thesis was the induction of an i vitro autologous T cell proliferation restricted to 
MHC class I molecules against the variable region of paraprotein light chain of plasmocytoma 
(VLIgPl) through autologous dendritic cells via retroviral transduction of human CD34
+ 
progenitor cells. The thesis aim was also to develop serum-free cult re conditions enabling 
the generation of mature DC without o er lineages generated to prepare large amounts of 
APC for in vitro studies.  
 
Most retroviral vectors contain a bacterial antibiotic-res stance gene such as neomycin that is 
strongly immunogenic. Its peptides will be presented on MHC class I molecules and activate 
CD8+ T lymphocytes, thus skewing the elicited immune response. In order to minimize such 
immune action against xenogenic peptides, aim of the thesis was also to construct a novel 
retroviral expression-cloning vector to direct the tumor-associated antigen of plasmocytoma 
fused with an artificial antibody-bin ing site such as FLAG to the plasma membrane via a 
glycosylphosphatidylinositol (GPI)-anchor. Thereby, transfected or transduced cells should be 
detected using monoclonal anti-FLAG antibodies.  
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2  Materials and methods 
 
 
2.1  Materials 
 
 
2.1.1  Bacteria strains  
 
DH10B (Resource Center of the German Hu a  Genome Project at the Max-Planck-Institute 
for Molecular Genetics, RZPD): 
F´ mcrA D(mrr-hsdRMS-mrcBC) F80dlacZDM15 DlacX74 deoR recA1 endA1 araD139 
D(ara-leu)7697 galU galK1 rpsL nupG. 
 
INVaF´ (Invitrogen BV): 
F´ endA1 recA1 hsdR17 (rk
-, mk
+) supE44 thi-1 gyrA96 relA1 f80lacZDM15 D(lacZYA-
argF)U169 l-. 
 
TOP10F´ (Invitrogen BV): 
F´ {lacIq Tn10 (TetR)} mcrA D(mrr-hsdRMS-msrBC) F80lacZDM15 DlacX74 recA1 
araD139 D(ara-leu)7697 galU galK rpsL (StrR) endA1 nupG. 
 
XL1-Blue (Stratagene GmbH): 
F´ ::Tn10proA+B+ lacIq D(lacZ)M15/recA1 endA1 gyrA96 (Nalr) thi hsdR17 (rk
-, mk
+) 
supE44 relA1 lac. 
 
 
2.1.2  Cell lines 
 
Hela (American Type Culture Collection, ATCC): 
Human cervical carcinoma (Chen, 1988). 
 
NIH/3T3 (ATCC): 
Murine embryonic fibroblasts (Jainchill et al., 1969). 
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Jurkat wild type (ATCC): 
Human acute T cell leukaemia, T lymphocyte (Gillis and Watson, 1980; Weiss et al., 1984). 
  
GP+E86 (ATCC): 
Ecotropic murine retrovirus packaging cell line (Markowitz et al., 1988). 
 
PG13 (ATCC): 
Pseudotyped murine retrovirus packaging cell line derived from TK-NIH/3T3 cells and based 
on the Gibbon ape leukemia virus, GaLV (Miller and Rosman, 1989; Miller et al., 1991). 
 
FNX-Eco Cells (provide  by Dr. Garry P. Nolan, Department of Molecular Pharmacology, 
Standford University School of Medicine): 
High titre ecotropic human retrovirus-prod cing cell line derived from 293T cells (Pear et al., 
1993; Yang et al., 1999). 
 
FNX-Ampho Cells (provided by Dr. Garry P. Nolan): 
High titre amphotropic human retrovirus-producing cell line derived from 293T cells (Pear   
et al., 1993; Yang et al., 1999). 
 
 
2.1.3  Chemicals 
 
The used fine chemicals were obtained from Applichem GmbH, Calbiochem-Novabiochem 
GmbH, ICN Biomedicals GmbH, Merck KGaA and Sigma-Aldrich Chemie GmbH. Distilled, 
deionized and ampura (sterile endotoxin-free) water were obtained from pharmacy of 
Hannover medical school (MHH).  
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2.1.3.1  Antibodies and fluorescence materials 
 
Antibodies and 
fluorescence Materials 
Clone Isotype Conjugate Producer 
CD1a BL6 IgG1 (Mouse) PE Immunotech GmbH 
CD3 UCHT1 IgG1, k (Mouse) PE DAKO 
CD14 MfP9 IgG2b FITC Becton Dickinson 
GmbH 
CD15 HI98 IgM, k (Mouse) PE PharMingen GmbH 
CD34 8G12 IgG1 (Mouse) FITC Becton Dickinson 
GmbH 
CD34 581 IgG1, k (Mouse) PE Becton Dickinson 
GmbH 
CD34 AC136 IgG2a (Mouse) FITC Miltenyi Biotec 
CD40 5C3 IgG1, k (Mouse) FITC PharMingen GmbH 
CD55 IA10 IgG2a, k (Mouse) Biotin, FITC, 
PE 
PharMingen GmbH 
CD83 HB15e IgG1, k (Mouse) FITC PharMingen GmbH 
CD86 (B70/B7-2) IT2.2 IgG2b, k (Mouse) Unconjugate, 
PE 
PharMingen GmbH 
Anti-FLAG M2   Biotin, FITC Sigma-Aldrich 
Chemie GmbH 
HLA-ABC W6/32 IgG2a (Mouse) FITC Serotec 
HLA-ABC B9.12.1 IgG2a (Mouse) Uconjugate, 
FITC 
Immunotech GmbH 
HLA-DR G46-6 
(L243) 
IgG2a, k (Mouse) FITC Becton Dickinson 
GmbH 
HLA-DR B8.12.2 IgG2b (Mouse) Unconjugate Immunotech GmbH 
HLA-DR Immu-357 IgG1 (Mouse) PE Immunotech GmbH 
Avidin   FITC Becton Dickinson 
GmbH 
Streptavidin   PE Becton Dickinson 
GmbH 
7AAD (7-amino-
actinomycin D) 
   PharMingen GmbH 
Propidium Iodide    PharMingen GmbH 
Isotype Controls DAK-GO1 IgG1 (Mouse) FITC, PE DAKO 
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2.1.3.2  Enzymes 
 
The used enzymes were obtained from Roche Diagnostics GmbH, Gibco BRL, MBI 
Fermentas Molecular Biology GmbH, New England BioLabs, Pharmacia, Promega, Serva, 
Sigma-Aldrich Chemie GmbH and Stratagene GmbH.    
 
 
2.1.3.3  Kits 
 
-CD34 MultiSort Kit (Miltenyi Biotec) 
-GFXTM PCR DNA and Gel Band Purification Kit (Amersham Pharmacia Biotech) 
-EndoFree Plasmid Maxi Kit (Qiagen GmbH) 
-NucleoSpinÒ Plasmid Kit (Macherey-Nagel GmbH) 
-Original TA CloningÒ Kit (Invitrogen BV) 
-Pan T Cell Isolation Kit (Miltenyi Biotec) 
-QIAprep Spin Miniprep Kit (Qiagen GmbH) 
-RNAzolTM B-Total RNA Isolation Reagent (Cinna Biotecx Labs Inc.) 
-SuperFectTM Transfection Reagent (Qiagen GmbH) 
 
 
2.1.3.4  Molecular weight standards 
 
-100 bp DNA Ladder (New England BioLabs) with 1517, 1200, 1000, 900, 800, 700, 600, 
500/517, 400, 300, 200, 100 bp fragments. 
 
-1 kb DNA Ladder (Gibco BRL) with 12216, 11198, 10180, 9162, 8144, 7126, 6108, 5090, 
4072, 3054, 2036, 1636, 1018, 517/506, 396, 344, 298, 220, 201, 154, 134, 75 bp fragments.  
 
-l DNA-HindIII Fragments (Gibco BRL) with 23130, 9416, 6557, 4361, 2322, 2027, 564 bp 
fragments. 
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2.1.3.5  Oligonucleotides 
 
The used Oligonucleotides were synthesized in MWG-B otech. The lyophilized primers were 
dissolved in distilled water at a concentration of 100 mg/ml, aliquoted and stored at -20°C. 
 
Oligonucleotide VLIg PCR primers (Sahota et al., 1997) 
Primer Location Orientation Sequence (5' è 3') 
Vk1&4 FR1 Sense GACATCSWGATGACCCAGTCTCC 
Vk2&6 FR1 Sense GAWRTTGTGMTGACTCAGTCTCC 
Vk3 FR1 Sense GAAATTGTGTTGACGCAGTCTCC 
Vk5 FR1 Sense GAAACGACACTCACGCAGTCTCC 
Jk1-4 FR4 Anti-sense ACGTTTGATHTCCACYTTGGTCCC 
Jk5 FR4 Anti-sense ACGTTTAATCTCCAGTCGTGTCCC 
Vl1 FR1 Sense CAGTCTGTSBTGACKCAGCCRCCY 
Vl2 FR1 Sense CAGTCTGCCCTGACTCAGCCTSSYT 
Vl3 FR1 Sense TCYTMTGWGCTGACTCAGSMM 
Vl7&8 FR1 Sense CAGRCTGTGGTGACYCAGGAGCCMTC 
Vl9 FR1 Sense CAGCCTGTGCTGACTCAGCCACCTTC 
JlC FR4 Anti-sense ACCKAGGACGGTSASCTKGGTSCC 
    
Designed oligonucleotide primers for a novel retroviral vector construction  
Primer Orientation Sequence (5' è 3') 
SacI NotI Start Signal Sense CGAGCTCGAAGGAAAAAAGCGGCCGCATGAC 
CGTCGCGCGG 
XbaI FLAG Signal Anti-sense TGCTCTAGAGCACTTGTCATCGTCGTCCTTGTA 
GTCACCCCACACGGCCGG 
XbaI ClaI GPI Sense TGCTCTAGAGCACCCATCGATGGGCCAAATAA 
AGGAAGTGG 
KpnI HindIII Stop GPI Anti-sense CGGGGTACCCCGCCCAAGCTTGGGCTAAGTCA 
GCAAGC 
XbaI 2YP999 Sense TGCTCTAGAGCAGACATCGTGATGACC 
ClaI 2YP999 Anti-sense CCCATCGATGGGGTTTAATCTCCAGTCG 
B = c + g + t, H = a + c + t, K = g + t, M = a + c, R = a + g, S = c + g, W = a + t, Y = c + t 
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2.1.3.6  Plasmids 
 
-pBI-EGFP vector containing enhanced green fluorescent protein (EGFP) ge e (Clontech 
GmbH) 
 
-pBluescript SK(+) phagemid (Stratagene GmbH) 
 
-pCRÒ2.1 vector (Invitrogen BV) 
 
-pSFbN1 retroviral vector containing neomycin resistance (NeoR) gene, kindly provided by 
Dr. Christopher Baum (Baum et al., 1995) 
 
-pSPORT1 vector containing the first 34 amino acids of DAF (clone DKFZp434P184, RZPD) 
 
-pT7T3D-PAC mod1 vector containing the last 37 amino acids of DAF (clone 
IMAGp998D23661, RZPD) 
 
 
2.1.3.7  Recombinant human cytokines and growth factors 
 
Factor   Producer 
Recombinant Human Flt-3 ligand (Flt-3L)   Immunex Corp, Tebu GmbH 
Recombinant Human Granulocyte-Macrophage Colony-
Stimulating Factor (GM-CSF) 
  
Tebu GmbH 
Recombinant Human Interleukin-3 (IL-3)  Tebu GmbH 
Recombinant Human Interleukin-4 (IL-4)  Tebu GmbH 
Recombinant Human Stem Cell Factor (SCF)  Amgen, Tebu GmbH 
Recombinant Human Transforming Growth Factor Beta 1 
(TGF-b1) 
  
Tebu GmbH 
Recombinant Human Tumor Necrosis Factor-Alpha 
(TNF-a) 
  
Tebu GmbH 
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2.1.4  Solutions and media 
 
2.1.4.1  Calcium phosphate precipitation method solutions for transfection of eukaryotic cells 
 
CaCl2 stock solution: 
  2 M CaCl2 in distilled water 
  Filter through 0.22 mM filter. 
Aliquot and store at -20°C. 
 
Chloroquine stock solution: 
50 mM Chloroquine in PBS 
Filter through 0.22 mM filter. 
Aliquot and store at -20°C. 
 
Na2HPO4 stock solution: 
  5.25 g Na2HPO4 in 500 ml of distilled water 
 
2 X HBS: 
  8.0 g NaCl 
  6.5 g HEPES sodium salt (Sigma-Aldrich Chemie GmbH) 
  10 ml Na2HPO4 stock solution 
Adjust the pH of the solution to exactly 7.0 using NaOH or HCl. 
Bring the volume up to 500 ml with distilled water.        
Check pH again, the pH is very important, it must be exactly 7.0 at RT. 
Filter through 0.22 mM filter. 
Aliquot and store at -20°C. 
 
 
2.1.4.2  Solutions and media for eukaryotic cells culture 
 
Media: 
 
-CellGroÒ DC serum-free medium (CellGenix) 
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-CellGroÒ SCGM serum-free medium (CellGenix) 
 
-Dulbecco´s modified Eagle´s medium, DMEM (Life Technologies) 
 
-Iscove´s modified Dulbecco´s medium, IMDM (Life Technologies) 
 
-RPMI 1640 (Life Technologies) 
 
-CellGroÒ DC serum-free medium complete (CellGroÒ DC-C) 
  CellGroÒ DC 
  2 mM L-glutamine  (Biochrom KG)
  100 U/ml Penicillin  (Biochrom KG) 
  100 mg/ml Streptomycin  (Biochrom KG) 
 
-CellGroÒ SCGM serum-free medium complete (CellGroÒ SCGM-C) 
  CellGroÒ SCGM 
  2 mM L-glutamine 
  100 U/ml Penicillin 
  100 mg/ml Streptomycin 
 
-DMEM complete (DMEM-C): 
  DMEM 
  10 % (v/v) FCS (PAA Laboratories GmbH) 
  2 mM L-glutamine 
  100 U/ml Penicillin 
  100 mg/ml Streptomycin 
 
-DMEM for packaging cell lines GP+E86 and PG13 (DMEM-P): 
  DMEM 
  10 % (v/v) Costar FCS (CytogenÒ) 
  2 mM L-glutamine 
  100 U/ml Penicillin 
  100 mg/ml Streptomycin 
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-HAT-selection medium for PG13 packaging cell line:
  DMEM-P 
  0.2 % (v/v) 500 X HAT (Roche Diagnostics GmbH) 
 
-HXM-selection medium (100 ml) for GP+E86 packaging cell line: 
  DMEM-P 
150 ml Hypoxanthine, 10 mg/ml in 0.1 N NaOH (Sigma-Aldrich Chemie 
GmbH) 
  2.5 ml Xanthine, 10 mg/ml in 0.1 N NaOH (Sigma-Aldrich Chemie GmbH) 
250 ml Mycophenolic acid, 10 mg/ml in 0.1 N NaOH (Sigma-Aldrich Chemie 
GmbH) 
  20-30 ml Concentrated HCl (to adjust pH) 
 
-Phoenix packaging cell lines selection medium: 
  DMEM-C 
  1 mg/ml Diphtheria toxin (Calbiochem-Novabiochem GmbH) 
  300 mg/ml Hygromycin B (Roche Diagnostics GmbH) 
 
-RPMI 1640 complete (RPMI-C) 
  RPMI 1640 
  10 % (v/v) FCS 
  2 mM L-glutamine 
  100 U/ml Penicillin 
  100 mg/ml Streptomycin 
 
 
Saline solutions: 
 
-Hank’s buffer saline solution, HBSS (pharmacy of MHH) 
 
-Phosphate buffered saline solution (PBS) with or without calcium and magnesium (pharmacy 
of MHH) 
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Others: 
 
-Ficoll-Hypaque gradient, specific gravity 1.077 g/ml (Seromed) 
 
-Trypsin/EDTA (PAA Laboratories GmbH) 
 
 
2.1.4.3  Solutions and media for bacteria culture 
 
Luria-Bertani (LB) medium, 1L: 
  10 g Bacto-trypone (Difco Laboratories) 
  5 g Bacto-yeast extract (Difco Laboratories) 
  10 g NaCl 
  950 ml Deionized water 
  Adjust the pH of the solution to 7.0 with NaOH and bring the volume to 1 liter. 
  Autoclave on liquid cycle for 20 min. 
  Allow solution to cool to 55°C. 
  Store at RT. 
 
LB agar plates, 1L: 
  Prepare LB medium as above, but add 15 g/L agar before autoclaving. 
  Autoclave on liquid cycle for 20 min. 
  Allow solution to cool to 55°C. 
  Add antibiotic (50 mg/ml of either ampicillin or kanamycin). 
  Pour into 10 cm plates. 
  Let harden, then invert and store at 4°C. 
 
X-Gal (5-bromo-4-chloro-3-indolyl-b-D-galactoside) stock solution (40 mg/ml): 
  Dissolve 400 mg X-Gal in 10 ml dimethylformamide. 
  Protect from light by storing in a brown bottle at -20°C. 
 
IPTG (isopropyl-b-D-thiogalactoside) stock solution (100 mM): 
  Dissolve 238 mg of IPTG in 10 ml deionized water. 
  Filter-sterilize and store in aliquots at -20°C. 
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X-Gal with/without IPTG LB plates:   
  Warm LB plates with the appropriate antibiotic at 37°C for 10 min. 
Pipet 40 ml of the X-Gal stock solution with/without 40 ml of the IPTG stock 
solution onto the center of each plate and spread evenly with a sterile spreader. 
Allow the solution to diffuse into the plate by incubating at 37°C for            
20-30 min. 
Pleats are now ready to use. 
 
SOC medium, 1L: 
  20 g Bacto-trypone 
  5 g Bacto-yeast extract 
  0.5 g NaCl 
  950 ml Deionized water 
  10 ml of 250 mM KCl stock solution 
Adjust pH to 7.0 with 5 M NaOH and bring the volume to 980 ml with 
deionized water. 
  Autoclave on liquid cycle for 20 min. 
  Allow solution to cool to 55°C. 
  Add 10 ml of filter-sterilized 2 M glucose stock solution. 
  Add 10 ml of 1 M sterile MgCl2 stock solution. 
  Store at RT or 4°C. 
 
TSS solution: 
  LB medium (without pH adjustment) 
  30 mM MgCl2 
  10 % (v/v) Polyethylene glycol 4000 
  5 % (v/v) DMSO (Sigma-Aldrich Chemie GmbH) 
  Autoclave on liquid cycle for 20 min. 
  Store at 4°C. 
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2.1.4.4  Standard buffer 
 
TAE 50 X buffer (1L): 
  242 g Tris base 
  57.1 ml Glacial acetic ac d 
  100 ml 0.56 M EDTA, pH 8.0 
Adjust the pH of the solution to 7.2 bring the volume to 1 liter with distilled 
water.         
 
6 X Sample buffer (6 X SB): 
  6 ml 50 X TAE buffer 
  44 ml Glycerine  
  0.05 % (w/v) Bromophenol blue and mix well 
 
Ethidium bromide: 
  10 mg/ml in distilled H20
 
 
2.1.5  Consumed materials 
 
-Cannulas and Syringes (B. Braun) 
-Cap lock reaction (0.5 ml, 1.5 ml and 2 ml) tubes (Eppendorf) 
-Cap lock sterile disposable polypropylene RNase-free (1.5 ml and 2 ml) tubes (Eppendorf) 
-Cryogenic vial, 2 ml (Nalge Nunc International) 
-Filter, 0.22 mm and 0.45 mm (Millipore GmbH) 
-Filter cap tissue culture (25 cm2, 75 cm2 and 175 cm2) flasks (Greiner GmbH) 
-Multiwell (6-, 24- and 96-well) tissue culture plates (Falcon, Greiner GmbH and Nalge Nunc 
International) 
-Petri dishes (Greiner GmbH) 
-Pipettes (Greiner GmbH) 
-Pipette tips (Eppendorf) 
-Sterile disposable polypropylene RNase-free tips (Eppendorf) 
-Tissue culture (60 and 100 mm) dishes (Nalge Nunc Int rnational) 
-Tissue culture (15 ml and 50 ml) tubes (Greiner GmbH) 
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2.1.6  Devices 
 
-1214 Rackbeta liquid scintillation counter (LKB) 
-2219 Multitemp II thermostatic circulator (LKB) 
-Biofuge 13 (Heraeus) 
-Cell culture incubators (Heraeus) 
-Cell-poratorÒ (Life Technologies) 
-Centrifuge 5415 (Eppendorf) 
-Centrifuge, model J2-21, rotor JA14 and JA17 (Beckmann) 
-Centrifuge, model J-6B (Beckmann) 
-Centrifuge, model J6-MC (Beckmann) 
-Diavert fluorescence microscope (Leitz) 
-Diavert light microscope (Leitz) 
-Digital-pH-meter (Knick) 
-EasijectTM plus electroporation (Eurogentec) 
-Eclipse TE 300 fluorescence microscope (Nikon) 
-FACScalibur with CellQuest software (Becton Dickinson) 
-G24 environmental incubator shaker (New Brunswick Scientific Co. Inc.)     
-Gel Doc 1000 (Bio-Rad Laboratories GmbH)  
-GFL water bath (H. Juergens & Co.)
-Horizontal electrophoresis (Bio-Rad Laboratories GmbH and Pharmacia) 
-Laminar air flow class 100 (Gelaire) 
-Magnetic cell separator, MACS (Miltenyi Biotec)
-Megafuge 2.0 R (Heraeus) 
-Minifuge T (Heraeus) 
-PHDTM 96-well cell harvester (Cambridge Technology, Inc.) 
-SpeedVacÒ plus SC 110A (Savant) 
-Sterile GARD hood (Baker Company, Inc.) 
-Thermocycler varius V45 (Landgraf) 
-Thermomagnetic stirrer, MR 2002 (Heidolph Instruments) 
-Thermomixer 5436 (Eppendorf) 
-Thermostat 5320 (Eppendorf) 
-UV-VIS Spectrophotometer, UV-1202  (Shimadzu Deutschland GmbH) 
-Vortex Genie 2TM (Bender and Hobein AG)
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2.2  Methods 
 
 
2.2.1  Microbiological methods 
 
2.2.1.1  Cultivation of competent cells 
 
The bacteria were streaked onto freshly prepared agar plats containing the appropriate 
selective antibiotic followed by incubation overnight at 37°C. The plates were used over a 
period of 6 weeks when stored at 4°C. 
 
A single colony was inoculated into 1-5 ml of LB medium containing the appropriate 
selective antibiotic and grown in a tube with a volume of at least 4 times the volume of 
culture with a constant shacking (100-250 rpm) for 12- 6 h at 37°C. Growth for more than   
16 h was not here performed since cells began to lyse leading to reduced plasmid yields.  
 
The growing bacteria were stored in 30 % glycerine LB medium at -80°C.  
 
 
2.2.1.2  Production of competent cells 
 
A single colony was peaked from a freshly streaked selective plate and a starter culture of     
2-5 ml LB medium containing the appropriate selective antibiotic was inoculated in a tube 
with a volume of at least 4 times the volume of culture. The tube was incubated for 8 h at 
37°C with vigorous shaking (300 rpm). 500 ml of the starter culture was diluted into 40 ml 
selective LB medium in a flask with a volume of at least 4 times the volume of culture. The 
flask was incubated at 37°C with vigorous shaking (300 rpm) to OD600 = 0.4. The flask was 
cooled on ice and the bacteria cells were harvested by centrifugation (2000 rpm) at 4°C for  
10 min. The bacteria cells were resuspended in 4 ml ice-cold TSS solution. 100-200 ml was 
aliquoted in sterile cap-lock eppendorf tubes (1.5 ml). The aliquots were stored at -80°C. 
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2.2.1.3  Transformation of competent cells with plasmid-DNA 
 
INVaF´ and TOP10F´ competent cells were transformed in the presence or absence of 0.5 M                 
b-mercaptoethanol, respectively following the manufacturer’s instructions (Original TA 
CloningÒ Kit, Invitrogen BV).  
 
XL1-Blue competent cells were transformed as following:
About 50 ng plasmid-DNA or 5-10 ml ligation reaction was mixed with 50-100 ml competent 
cells-containing vials by stirring gently with the pipette tips and incubated on ice for 30 min. 
After heat shock for exactly 90 sec at 42°C without mix or shake, th  vials were cooled for    
3 min on ice. 250 ml of LB medium was added and the vials were incubated for 1 h at 37°C 
with shaking gently.  
 
50 ml, 100 ml and 200 ml from each transformation vial were spread on separate, labeled agar 
plates containing the appropriate selective antibiotic and X-Gal (and IPTG in TOP10F´ 
competent cells). After the liquid was absorbed the plates were inverted and placed in a 37°C 
incubator for at least 18 h. Plates were then shifted to 4°C for 2-3 h before selecting colonies 
for analysis to allow proper color development. 
 
 
2.2.2  Molecular biological methods  
 
2.2.2.1  RNAzolTM B-total RNA isolation method 
 
Homogenization: 
0.1-2 ´  107 mononuclear cells (MNC) of plasmocytoma patient (E.G) have been washed in  
10 ml PBS by centrifugation for 3 min at 1600 rpm. The supernatant was removed and the 
cells were lysed in RNAzolTM B (0.2 ml/106 cells, Cinna Biotecx Labs Inc.) by repeated 
pipetting.  
 
Phase separation: 
Chloroform (1/10 volume of homogenate) was added and the homogenate was shaken 
vigorously for 15-30 sec. The sample was stored on ice for 5 min and centrifuged at       
12000 x g for 15 min at 4°C. Following centrifugation, the sample forms two phases: the 
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lower blue phenol-ch oroform phase, containing DNA and proteins and the upper colorless 
aqueous phase, containing RNA. The volume of the aqueous phase is about 50 % of the initial 
volume. 
 
RNA precipitation: 
The aqueous phase was transferred to a clean tube and equal volume of cold isopropanol was 
added. The sample was stored f  1 h at 4°C and centrifuged at 12000 x g for 15 min at 4°C.  
 
RNA wash: 
The supernatant was removed and the RNA pellet was washed once with 1 ml 75 % ethanol. 
After shaking to dislodge the pellet from the side of the tube the pellet was centrifuged for    
8 min at 7500 x g at 4°C. 
 
RNA solubilization: 
The pellet was dried by air-dry ng or under vacuum (5-10 min). It is important not to let the 
RNA pellet dry completely, as this greatly decreases solubility and can lead to RNA 
degradation. The RNA pellet was dissolved in 50 ml autoclaved 0.1 % (v/v) diethyl 
pyrocarbonate treated-water (DEPC-water) by passing the solution through a pipette tip 
and/or incubating for 10-15 min at 55-60°C. The RNA was stored at -80°C until using. 
 
Sterile disposable RNase-fre  polypropylene tubes and tips were used throughout the 
procedure.  
 
 
2.2.2.2  Plasmid preparation 
 
Bacterial cultures for plasmid preparation should always be grown from a single colony 
picked from a freshly streaked selective plate. Subculturing directly f om glycerol stocks, agar 
stabs and liquid cultures is poor microbiological practice and may lead to loss of the plasmid. 
Inoculation from plates that have been stored for a long time was also considered as having 
lost or mutation of the plasmid. The esir d clone should be streaked from a glycerol stock 
onto a freshly prepared agar plate containing the appropriate selective antibiotic so that single 
colonies can be isolated. 
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2.2.2.2.1  Mini-preparation of plasmid using QIAprep Spin Miniprep Kit (Qiagen GmbH) or 
NucleoSpinÒ Plasmid Kit (Macherey-Nagel GmbH) 
 
The two methods are identical and designed for rapid and small-scale (20-40 mg) preparation 
of highly pure plasmid DNA (< 10 kb) from 1-8 ml of overnight E. coli culture. The mini-
preparation of plasmid was carried out following the manufacturer’s instructions. Briefly, the 
pelleted bacteria were resuspended in RNase A-containing buffer 1 and plasmid DNA was 
librated from the E. coli host cells by SDS/alkaline lysis (buffer 2). Buffer 3 neutralized the 
resulting lysate and created appropriate conditions for binding of plasmid DNA to the silica 
membrane in QIAprep spin or NucleoSpin plasmid column. SDS precipitate and cell debris 
were pelleted by the centrifugation step and the supernatant was loaded o to QIAprep spin or 
NucleoSpin plasmid column. If host strains with high nuclease levels were used, a washing 
step with buffer PB (QIAprep Spin Miniprep Kit) or AW (NucleoSpinÒ Plasmid Kit) was 
recommended. Contaminations like salts, metabolites and soluble macromolecular cellular 
components were removed by simple washing with ethanolic buffer. Pure plasmid DNA was 
finally eluted with 50 ml distilled water and stored at -20°C.       
 
 
2.2.2.2.2  Maxi-preparation of plasmid using EndoFree Plasmid Maxi Kit (Qiagen GmbH) 
 
This method was designed for purification of up to 500 mg endotoxin-free plasmid DNA. 
Endotoxine-free plasmid DNA improves transfection into sensitive eukaryotic cells and is 
essential for gene therapy research. 
 
A single colony was peaked from a freshly streaked selective plate and a starter culture of     
2-5 ml LB medium containing the appropriate selective antibiotic was inoculated in a tube 
with a volume of at least 4 times the volume of culture. The tube was incubated for 8 h at 
37°C with vigorous shaking (300 rpm). The starter culture was diluted into 100 ml or 250 ml 
selective LB medium for high-copy plasmids or low-copy plasmids, respectively in a flask 
with a volume of at least 4 times the volume of culture. The flask was incubated at 37°C for 
12-16 h with vigorous shaking (300 rpm). The bacteria cells were harvested by centrifugation 
(6000 x g) at 4°C for 10 min. All traces of supernatant were removed by inverting the open 
centrifuge tubes until all medium had been drained. The bacteria pellet was resuspended 
completely in 10 ml RNase A-containing buffer (P1) by vortexing. Plasmid DNA was librated 
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from the E. coli host cells by addition of 10 ml lysis buffer (P2) and mixing gently but 
thoroughly by inverting 4-6 times and incubation at RT for exactly 5 min. A vessel of 
sufficient size was used to allow complete mixing of the lysis buffer. After addition of 10 ml 
chilled buffer 3 and mixing immediately but gently by inverting 4-6 times, a fluffy white 
precipitate containing genomic DNA, proteins, cell debris and SDS became visible. The lysate 
was transferred into the screwed cap QIAfilter cartridge immediately to prevent later 
disruption of precipitate layer and incubated at RT for 10 min. A precipitate containing 
genomic DNA, proteins and detergents was floated and formed a layer on top of the solution.  
After the cap was removed, the lysate was filtered through the QIAfilter using the plunger 
into a 50 ml tube. Approximately 25 ml of the lysate was recovered after filtration. To obtain 
endotoxin-free plasmid DNA, 2.5 ml buffer ER was added to the filtered lysate. After mixing 
by inverting the tubes approximately 10 times and incubation on ice for 30 min, the filtered 
lysate was transferred to the equilibrated QIAGEN-tip 500 and moved through it by gravity. 
After washing twice with 30 ml buffer QC, the DNA was eluted with 15 ml Buffer QN. The 
eluted DNA was collected in 30 ml endotoxin-free tube and precipitated by 10.5 ml RT 
isopropanol and centrifuged immediately at 15000 x g for 30 min at 4°C. The supernatant was 
carefully decanted and DNA pellet was washed with 5 ml endotoxin-fre , RT 70 % ethanol. 
Air-dry (5-10 min) plasmid pellet was redissolved, by rinsing the walls to recover all DNA, in 
a suitable volume of endotoxin-free water (ampura water). It was of big importance not to let 
the plasmid pellet dry completely, as this greatly decreases solubility. Endotoxin-free pure 
plasmid DNA was stored at -20°C. Endotoxine-free plastic pipettes and tubes were used for 
elution and subsequent stps. 
 
 
2.2.2.3  Enzymatic modification of nucleic acids 
 
2.2.2.3.1  Treatment of isolated total RNA with DNase 1, RNase-free (och  Diagnostics 
GmbH) 
 
To purify RNA from genomic DNA, 10 U (1 ml) DNase 1, RNase-fr e was added to 2 mg 
total RNA in a final volume of 10 ml of 1 X buffer followed by incubation for exactly 15 min 
at RT. To stop the reaction, 1 ml of 25 mM EDTA (Life Technologies) was added followed by 
incubation for 10 min at 65°C. 
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2.2.2.3.2  First-strand cDNA synthesis (reverse transcription) 
 
In a sterile RNase-fr e microcentrifuge tube, 0.5 mg (1 ml) oligo (dT)15 primer (Promega) was 
added to 2 mg total RNA (treated with or without DNase 1, RNase-free) in a total volume of 
12 ml DEPC-water. The tube was heated to 70°C for 5 min to linearize RNA folding within 
the template and immediately cooled on ice to prevent RNA folding from reforming followed 
by briefly centrifugation to collect the fluid at the bottom of the tube. The following 
components were added to the annealed primer/template in the order shown: 
   
5 X M-MLV reaction buffer 5 ml 
10 mM dNTP´s (Promega) 1.25 ml 
25 U rRNasinÒ ribonuclease inhibitor (Promega) 0.625 ml 
DEPC-water 5.125 ml 
200 U M-MLV reverse transcriptase (Promega) 1 ml 
 
The tube was mixed gently by flicking and incubated for 60 min at 42°C. After the reaction 
was stopped by incubation at 75°C for 10 min, the tube was cooled on ice and reverse 
transcriptase-polymerase chain reaction (RT-PC ) was performed immediately thereafter.  
 
 
2.2.2.3.3  Polymerase chain reaction (PCR) 
 
A sample of the obtained cDNA (1/3 to 1/5) or 10-100 ng of plasmid DNA was used as a 
template in the polymerase chain reaction (PCR) using a mixture of 5' oligonucleotide FWR1 
primers specific for the expressed V or V  families together with a mixture of downstream  
3' primers specific for J or J  genes (Sahota et al., 1997) or appropriate designed sense and 
anti-sense primers, respectively. In general, the PCR was carried out in a 50 ml volume
containing: 
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10 X PCR buffer with 15 mM MgCl2  5 ml 
10 mM dNTP´s 1 ml 
Primers 20 pmol each primer 
DNA template 1/3 to 1/5 cDNA or 10-100 ng plasmid DNA 
Sterile water to a total volume of 49 ml  
Taq polymerase (Promega) 2.5 U 
 
Amplification consisted of an initial denaturation step of 5 minutes at 94°C, followed by     
30-35 cycles of 94°C for 1 minute, 55-6 °C for 1 minute and 72°C for 1 minute, with a fin l 
extension step of 5 minutes at 72°C. At least two independent PCR amplifications were 
performed per test. Reaction without DNA template was used as negative control. The PCR 
product was stored at 4°C until usage.  
 
                                           
2.2.2.3.4  DNA digestion with restriction endonucleases 
 
Most of the used restriction endonucleases were obtained from (New England BioLabs). 
Cleaving DNA substrates with restriction endonucleases was performed following the 
manufacturer’s instructions. Generally, 10 U (1 ml) of enzyme was added to 1 mg of purified 
DNA in a final volume of 10 ml of the appropriate 1 X NEBuffer followed by incubation for  
1 h at the recommended temperature (37°C for most restriction enzymes). The enzyme was 
always the last component added to the reaction (reaction components should be mixed prior 
to addition of enzyme). Supercoiled plasmids generally required more than I U/g to be 
cleaved completely. 
 
Cleaving a DNA substrate with two restriction endonucleases simultaneously (double 
digestion) was carried out for time saving. The best NEBuffer was selected to provide 
reaction conditions that amenable to both restriction endonucleases (to ensure almost 100 % 
activity). The number of units of enzyme or incubation time of the reacti n was adjusted to 
compensate for slower rate of cleavage in case of using sub-optimal NEBuffer. In the case 
that no single NEBuffer was found to satisfy the buffer requirements of both enzymes, the 
reactions were done sequentially. Firstly, cleavage with the restriction endonucleases that 
required the lower salt reaction conditions was done and then the salt concentration of the 
reaction was adjusted (using a small volume of a concentrated salt solution) to approximate 
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the reaction conditions of the second restriction endonuclease. After addition the second 
endonuclease, the reaction was incubated to complete the second digestion. In the case that 
bovine serum albumin (BSA) was a buffer requirement for either enzyme, it was added to the 
double digest reaction because it did not inhibit any restriction enzyme. The final 
concentration of glycerol in any reaction should be less than 10 % to minimize the possibility 
of star activity. To avoid this situation, an increase in total reaction volume was necessary.  
 
 
2.2.2.3.5  Ligation 
 
To cloning the gel purified restriction DNA fragments and PCR products, ligation reaction 
was performed with T4 DNA ligase (Roche Diagnostics GmbH). The Original TA CloningÒ 
Kit with linearized pCRÒ2.1 vector (Invitrogen BV) provides a quick, one-step cloning 
strategy for the direct insertion of a PCR product into plasmid vector. The linearized vector 
has single 3`deoxythymidine (T) residues. This allows PCR inserts to ligate efficiently with 
the vector. The ligation reaction was performed with 1:1 or 1:3 (vector:insert) ratio in a 10 ml 
volume as follows: 
  
Gel purified PCR product or restriction DNA fragment X ml 
10 X ligation buffer 1 ml 
Vector Y ml 
Sterile water    to a total volume of 9 ml 
T4 DNA ligase (4.0 Weiss units) 1 ml 
 
The ligation reaction was incubated overnight at exactly 14°C. The ligation reaction was 
stored at -20°C until ready for transformation. 
 
 
2.2.2.3.6  Sequencing  
 
Sequencing was performed by MWG-Biotech sequencing service using the M13 Reverse 
primer and M13 (-20) forward primer.  
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2.2.2.4  Agarose Gel electrophoresis 
 
To visualize the isolated total RNA and separate the DNA fragments, agarose gel 
electrophoresis was used. 0.5 g agarose (Serva) in 50 ml 1 X TAE was boiled in a microwave. 
Before pouring the gel on electrophoresis plate, 2.5 ml ethidium bromide (10 mg/ml in 
distilled H20) was added. Samples with (1/5 volume of sample) 6 X sample buffer (6 X SB) 
were loaded on the soaked plates in electrophoresis chamber filled with 1 X TAE. 
Electrophoresis was done at » 100 V until the samples reached appropriate distance. The 
samples were visualized by Gel Doc 1000 (Bio-Rad) and analysed by molecular analysis 
software (Bio-Rad).  
 
 
2.2.2.5  Gel-DNA extraction and purification 
 
Gel-DNA extraction and purification were carried out using GFXTM PCR DNA and Gel Band 
Purification Kit (Amersham Pharmacia Biotech) f llowing the manufacturer’s instructions. 
Briefly, 300 mg (the maximum weight that can processed with this procedure) of gel slice was 
dissolved in 300 ml capture buffer and mixed vigorously by vortexing and incubated at 60°C 
(5-15 min) until the agarose was completely dissolved. The sample was passed through the 
GFX column to capture the DNA onto the glass fiber matrix. Matrix-bound DNA was washed 
with an ethanolic buffer to remove salts and other contaminants. The purified DNA was 
eluted from GFX column in 50 ml distilled water and stored at -20°C.   
 
 
2.2.2.6  Quantification of nucleic acids 
 
2.2.2.6.1  Photometric determination of RNA and DNconcentration 
 
To determine the concentration and purity of the isolated total RNA and plasmid obtained 
from maxi-preparation method, the absorption of diluted solution was measured by UV 
spectrophotometer at 260 nm and 280 nm. The dilution was performed to make the absorption 
between 0.1 and 1.0 OD. 
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The used equations are: 
RNA concentration (mg/ml) = absorbance at 260 nm ´ dilution factor ´ 40 ´  1000 
DNA concentration (mg/ml) = absorbance at 260 nm ´ dilution factor ´ 50 ´  1000  
Purity = absorbance at 260 nm/absorbance at 280 nm 
 
 
2.2.2.6.2  Agarose gel electrophoretic determination of DNA concentration 
 
Quantitative analysis by an agarose gel electrophoresis using l DNA-HindIII Fragments as 
mass reference was applied to determine the concentration of gl purified DNA and plasmid 
obtained from mini-preparation method. 
 
 
2.2.3  Cell culture 
 
2.2.3.1  General cell culture 
 
Generally, adherent and suspension cells were grown in a 37°C incubator containing 5 % 
CO2. The saturated cultures were splited every 3 days. Cell density was maintained between 
105-106 cells/ml. To split and passage adherent cells, the cells were gently rinsed with PBS 
and trypsinized until the cells were easily detached. Trypsinization was quenched with 
medium prior to subculturing in fresh medium.  
 
 
2.2.3.1.1  Cell counts 
 
Suspension and trypsinized viable cell counts were performed using a Neubauer chamber 
(Hawksley & Sons Limited) with at least 200 cells being counted per sample. Cell viability 
was assessed using trypan blue exclusion (Sigma-Aldrich Chemie GmbH).  
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2.2.3.1.2  Cell freezing 
 
To freeze suspension and trypsinized cells, the cells were centrifuged at 500 x g for 5 min and 
the media were removed. Immediately 1 ml of cold freezing solution (90 % heat-inactivated 
fetal calf serum, 10 % DMSO) per 106 cells was added and the cells were transferred to a cold 
2 ml cryogenic vial. After that the vial was placed overnight at -70°C and transferred to liquid 
nitrogen on the following day.  
 
 
2.2.3.1.3  Cell thawing 
 
To thaw the freezing cells, one vial was removed from liquid nitrogen and thawed rapidly at 
37°C. Immediately 1 ml medium was added to the freezing vial and the cells were gently 
transferred to a 15 ml sterile conical screw cap tube. To allow for osmotic equilibrium, 10 ml 
medium was gently added and the tube was mixed by inverting. After the cells were 
centrifuged at 500 x g for 5 min and the supernatant was removed, the cells were resuspended 
in 10 ml medium (105- 6 cells/ml) and cultured in filter cap 25 cm2 tissue culture flasks at 
37°C and 5 % CO2.  
 
 
2.2.3.2  Cell separation 
 
2.2.3.2.1  Isolation of peripheral blood mononuclear cells (MNC) by density gradient 
centrifugation 
 
Cord blood (CB) samples from normal full-term deliveries, human bone marrow (BM) from 
healthy donors and plasmocytoma patient (E.G) and G-CSF mobilized peripheral blood (PB) 
were used in this study. MNC were separated on Ficoll-Hypaque gradient (specific gravity   
1.077 g/ml) as follows: 
Diluted cells (35 ml) with PBS containing 1 % human serum albumin (pharmacy of MHH) 
and 0.4 % sodium citrate (pH 7.2) were carefully layered over 15 ml Ficoll in a 50 ml conical 
tube and centrifuged at 400 x g for 30 min at RT without brake. In case of BM and PB, cells 
were diluted in PBS containing 100 U/ml DNase with or without 0.02 % collagenase B 
(Roche Diagnostics GmbH), respectively in the presence of 2.5 mM/L MgCl2 and were 
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shaken gently at RT for 45 min before separation on Ficoll to release cells and decrease 
clumps-formation. After the upper layer (diluted autologous serum) was aspirated, the 
undisrupted mononuclear cell layer at the interphase was transferred to a new 50 ml conical 
tube. The cells were washed twice with PBS, resuspended in appropriate volume of PBS and 
counted. All cell clumps were removed by passing cells through 30 mm nylon mesh. To lyse 
remaining erythrocytes, cell pellet was incubated at RT for 30 sec in sterile distilled water.  
 
 
2.2.3.2.2  Isolation of monocytes 
 
Autologous monocytes (Mo) were obtained from the same G-CSF mobilized peripheral blood 
by plastic adherence of MNC. After 2 h, nonadherent cells were removed by 3 X gently
washing with PBS. 
 
 
2.2.3.2.3  Isolation of CD34+ haematopoietic progenitor cells 
 
CD34+ progenitor cells were separated from MNC by magnetic cell sorting using CD34 
MultiSort Kit (Miltenyi Biotec) following the manufacturer’s instructions. The CD34 
MultiSort Kit allows the multi-parameter sorting of haematopoietic progenitor cells. First, 
CD34+ cells are positively selected from peripheral blood, bone marrow r cord blood using a 
direct magnetic labelling system. Using MultiSort technology, the CD34 MultiSort 
MicroBeads have been subsequently released from the cells. Finally, the selected cell 
population have been magnetically labeled and resorted for other markers. After two cycles of 
magnetic separation, the purity of CD34+ progenitor cells measured by flow cytometric 
analysis using noncross blocking antibody, HPCA-2 FIT  (Becton Dickinson) was about     
98 %.  
 
 
2.2.3.2.4  Isolation of untouched CD3+ T cells  
 
Autologous T cells were purified from MNC of the same G-CSF mobilized peripheral blood 
by negative selection using the Pan T Cell Isolation Kit (Miltenyi Biotec) following the 
manufacturer’s instructions. The Pan T Cell Isolation Kit is an indirect magnetic labelling 
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system for the isolation of untouched T cells from human peripheral blood mononuclear cells 
by magnetic depletion of B cells, monocytes, NK cells, dendritic cells, early erythroid 
precursor cells, platelets and basophils. A cocktail of CD11b, CD16, CD19, CD36 and CD56 
antibodies was used for the depletion of non-T cells. Excellent recoveries of highly pure 
untouched T cells were achieved by retaining the magnetically labeled non-T cells on an LS 
Column. T cells isolated by using the Pan T Cell Isolation Kit can be used in functional assays 
and signal transduction studies where a direct labelling of a T cell marker for positive 
selection was avoided. 
 
 
2.2.3.3  Expansion of BM-CD34+ progenitor cells 
 
Ex vivo expansion of CD34+ progenitor cells facilitates the identification of culture conditions 
useful to generate DC to study their biology and their retroviral transduction for 
immunotherapeutic purposes (Glimm et al., 1998). To test the ability to expand CD34+ cells 
in serum-free medium, the increase in cell counts of BM-CD34+ cells (5 ´ 104 cells/ml) 
cultured in complete serum-containing medium IMDM or RPMI-1640 was compared with 
that cultured in complete serum-f ee medium CellGroÒ SCGM or CellGroÒ DC containing 
one of the two following cytokine cocktails: Flt-3L (150 ng/ml), IL-3 (100 ng/ml), SCF      
(50 ng/ml) and TGF-b1 (0.5 ng/ml) or Flt-3L (300 ng/ml), IL-3 (100 ng/ml) and SCF        
(100 ng/ml). Cultures were incubated for 7 days at 37°C in a humidified 5 % CO2-in-air 
atmosphere.  
 
 
2.2.3.4  Generation of human CD34+-derived dendritic cells 
 
2.2.3.4.1  Generation of human CD34+-derived dendritic cells with cytokines under serum-
free conditions 
 
CB-CD34+ cells (5 ´104 cells/ml) seeded into 24-well plate (Greiner GmbH) were cultured in 
complete serum-free medium (CellGroÒ DC) containing the following cytokines that 
specifically reported for CB (Bello-Fernandez et al., 1997): Flt-3L and GM-CSF (100 ng/ml 
each), SCF (20 ng/ml), TGF-b1 (0.5 ng/ml) and TNF-a (10 ng/ml) for 14 days at 37°C and    
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5 % CO2. The culture medium was exchanged at weekly intervals. The density of cells did not 
exceed 105 cells/ml. 
  
Also PB-CD34+ cells were cultured under the above conditions but with the following 
different cytokine cocktails specifically reported for PB (Garbe et al., 1998): Flt-3L           
(150 ng/ml), IL-3 (100 ng/ml), SCF (50 ng/ml) and TGF-b1 (0.5 ng/ml) for 1st week, Flt-3L 
(150 ng/ml), GM-CSF (100 ng/ml), IL-4 and SCF (50 ng/ml each) and TGF-b1 (0.5 ng/ml) 
for 2nd week and Flt-3L (150 ng/ml), GM-CSF (100 ng/ml), IL-4 and SCF (50 ng/ml each), 
TGF-b1 (0.5 ng/ml) and TNF-a (2 ng/ml) for 3rd and 4th weeks. At day 26, 20 ng/ml TNF-a 
was added to induce maturation.  
 
 
2.2.3.4.2  Generation of human CD34+-derived dendritic cells with phorbol ester (PMA) 
under serum-free conditions 
 
CB- or PB-CD34+ cells at a concentration of 5 ´ 104 cells/ml were cultured in 24-wel plate 
containing complete serum-free medium (CellGroÒ DC). Cultures were stimulated with       
15 ng/ml PMA (Sigma-Aldrich Chemie GmbH) and incubated for 7 days at 37°C and 5 % 
CO2. PB-CD34
+ cells were also stimulated with PMA plus 10 ng/ml TNF-a or plus 100 ng/ml 
ionomycin (Calbiochem-Novabiochem GmbH). Expanded BM-CD34+ cells in complete       
CellGroÒ SCGM containing Flt-3L (300 ng/ml), IL-3 (100 ng/ml) and SCF (100 ng/ml) were 
stimulated too with PMA.  
 
 
2.2.3.5  Transfection 
 
2.2.3.5.1  Transfection of cells via electroporation 
 
Cells (0.1-2 ´  107) were centrifuged at 700 x g washed once in cell culture medium without 
serum or glutamine and resuspended in a final volume of 400-1000 µl medium containing 
retroviral vector (10-40 mg). Electroporations were carried out in 0.4 cm electrode gab 
cuvettes at different voltage and capacity using Cell-poratorÒ (Life Technologies) or 
EasijectTM plus electroporation (Eurogentec) at room temperature or 4°C. Cells were grown in 
cell culture medium supplemented with 10 % FCS, 2 mM glutamine, 100 U/ml penicillin, and 
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100 µg/ml streptomycin at 37°C and 5 % CO2. After 48-72 h cells
 were analyzed for 
transfection by flow cytometer.  
 
 
2.2.3.5.2  Transfection of cells via SuperFectTM T ansfection Reagent (Qiagen GmbH) 
 
SuperFectTM Transfection Reagent represents a new class of activated-dendrimer transfection 
reagent designed for outstanding transfection results (Tang t al., 1996). It possesses a defined 
spherical architecture, with branches radiating from  cent al core and terminating at charged 
amino groups. It assembles DNA into compact structures, optimizing the entry of DNA into 
the cells. SuperFect-DNA complexes possess a net positive charge that allows them to bind to 
negatively charged receptors (e.g. ialylated glycoproteins) on the surface of eukaryotic cells. 
Once inside the cell, SuperFect reagent buffers the lysosome after it has fused with the 
endosome, leading to pH inhibition of lysosomal nucleases. This ensures stability of 
SuperFect-DNA complexes and the transport of intact DNA to the nucleus.  
 
Different cell numbers (0.1-2.5 ´  106) were seeded in 100-mm tissue culture dishes the day 
before transfection in order to determine the optimal transfection conditions. 10 mg retroviral 
vector diluted in 300 ml cell growth medium containing no serum, proteins or antibiotics was 
combined with 60 µl of SuperfectTM Transfection Reagent at room temperature for 10 min 
followed by the addition of 3 ml cell growth medium containing all additives including serum 
and antibiotics. The medium of the overnight cultures was removed and replaced with a 
mixture of Superfect-DNA. The complex incubation time on cells was 2.5 h. Analysis was 
performed 48 h post-transfection. 
 
 
2.2.3.5.3  Transfection of  adherent cells via calcium phosphate precipitation method (Pear    
et al., 1993): 
 
A total of 2 ´ 106 adherent cells were cultured in 3 ml medium in 60-mm tissue culture dishes 
(Nalge Nunc International) the night prior to transfection. About 5 min prior to transfection, 
chloroquine (a final concentration of 25 mM) was added to each dish to inhibit lysosomal 
DNases by neutralizing vesicle pH. To a 15 ml tube the following components were added in 
the order shown: 
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  5-10 mg (» 5-10 ml) DNA (DNA was added in a drop to a side of tube)
» 429-434 ml sterile distilled water (DNA was washed to bottom of tube      
with water) 
  61 ml 2 M CaCl2 (the solution was mixed thoroughly with finger tapping) 
  500 ml total volume 
500 ml 2 X HBS (The solution was vigorously b bbled with automatic pipettor 
for 15 sec) 
 
HBS/DNA solution was added immediately dropwise to the above medium. After dishes were 
rocked gently forward and backward a few times to distribute DNA/CaPO4 particles, the cells 
were incubated at 37°C and 5 % CO2 for 24 h. Subsequently, the medium was changed to      
3 ml fresh 10 % FCS medium. After 24-48 h cells were analyzed for transfection by flow 
cytometer.  
  
 
2.2.3.6  Working with retroviruses 
 
2.2.3.6.1  Growing retroviral packaging cells 
 
Ecotropic and pseudotyped murine retrovirus packaging cells (GP+E86 and PG13, 
respectively) were cultured in DMEM-P medium at 37°C in 5 % CO2. At least one week 
before transfection or infection, GP+E86 and PG13 cells were cultured in HXM- o  HAT-
selection medium, respectively. 
 
Human ecotropic and amphotropic packaging cells (FNX-Eco and FNX-Ampho) were 
cultured in DMEM-C medium at 37°C in 5 % CO2. At least one week before transfection or 
infection, the cells were cultured in DMEM-C medium that contained diphtheria toxin         
(1 mg/ml) for selection of the ecotropic and amphotropic envelope gene and hygromycin B 
(300 mg/ml) for selection of the gag-pol genes. 
 
The work with transfected ecotropic and non-transfected packaging cells were occurred in S1 
(safety level 1) labor but that with transfected or infected amphotropic and pseudotyped 
packaging cells were occurred in S2 (safety level 2) labor. 
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2.2.3.6.2  Virus production 
 
The ecotropic and amphotropic packaging cells were transfected with the retroviral vector-
DNA via electroporation, calcium phosphate precipitation method or SuperFectTM 
Transfection Reagent. Mock (no retroviral vector-DNA) transfected cells were used as 
negative control. To monitor the transfection efficacy, the cells were transfected with 
retroviral vectors containing EGFP. Cultures were maintained at 37°C and 5 % CO2 for      
24–48 h, then at 32°C and 5 % CO2 for 16–24 h. Viral supernatants were harvested and 
filtered using a 0.45 mm filter (Millipore GmbH), then stored at -80°C. FNX-Eco virus tocks 
with titers > 1 ´ 106 colony-forming units (CFU) per ml, as determined by titration on 
NIH/3T3, were used for transduction of murine pseudotyped packaging cells, PG13. 
 
 
2.2.3.6.3  Retroviral transduction of murine pseudotyped packaging cells, PG13 
 
A total of 2 ´ 106 PG13 cells were cultured in 12 ml medium in 100-mm tissue culture dishes. 
Following overnight incubation, the packaging cells were overlaid with 10 ml thawed 
retrovirus-containing supernatants (> 1 ´ 106 CFU/ml) or no retrovirus-containi g supernatant 
(mock) obtained from FNX-Eco packaging cells supplemented with protamine sulphate       
(5 mg/ml, Sigma-Aldrich Chemie GmbH) and incubated at 37°C in 5 % CO2 for 16-24 h. At 
72 h post infection, viral supernatants were harvested in complete serum-free medium 
CellGroÒ SCGM supplemented with 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml 
streptomycin and filtered using a 0.45 mm filter, then stored at -80°C. General 
recommendation for harvesting the retrovirus-conta ning supernatants was at 32°C. Here, 
pseudotype retrovirus-containing supernatants were harvested at 37°C because PG13 rapidly 
looses viral titer when grown at the lower temperature (Re ves et al., 2000). Virus stocks with 
titers > 5 ´ 105 CFU/ml, as determined by titration on Hela, were used for transduction of 
human CD34+ progenitor cells. 
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2.2.3.6.4  Retroviral transduction of CD34+ haematopoietic progenitor cells 
 
Different methods were used for retroviral transduction of CD34+ haematopoietic progenitor 
cells in serum-free medium to determine the optimal transduction conditions. Firstly, CD34+ 
progenitor cells (5 ´ 104) were stimulated for 48 h with Flt-3L (300 ng/ml), IL-3 (100 ng/ml) 
and SCF (100 ng/ml) in complete serum-fr e edium CellGroÒ SCGM. Subsequently, cells 
were infected with 1 ml mock or undiluted amphotropic or pseudotyped viral supernatants      
(> 5 ´  105 CFU/ml, made in serum-free medium) in the presence of protamine sulphate         
(5 mg/ml) and cytokines with or without centrifugation at 1000 x g for 2 h at room 
temperature. After that cells were incubated at 37°C in 5 % CO2. On the next day, 
supernatants were removed and cells were cultured in fresh medium supplemented with 
cytokines. Three rounds of consecutive transductions were performed on days 3, 5 and 7, 
respectively. The efficiency of the transduction was monitored one week after the last 
infection.  
 
Cells were also transduced by adhesion on the recombinant human fibronectin fragments  CH-
296, RetroNectin (Takara) as follows (Hanenberg et al., 1996): 
Non-tissue culture treated (24-well) plates (Greiner) were coated with 420 ml 96 mg/ml 
RetroNectin at RT for 2 h. The CH-296 solution was removed and the plates were blocked 
with 420 ml PBS/2 % Human serum for 30 min at RT. After plates were washed with 
HBSS/2.5 % (v/v) 1M HEPS (Applichem GmbH), 1 ml cells/undiluted amphotropic or 
pseudotyped viral supernatant with cytokines were added and incubated overnight at 37°C
and 5 % CO2. On the next day cells were harvested, wash  and cultured in fresh medium 
containing cytokines at 37°C and 5 % CO2 in a new 24-well plate. The transduction efficacy 
was monitored after 3 to 5 days by flow cytometric analysis or fluorescence microscope. 
 
 
2.2.3.6.5  Viral titer determination 
 
The titer of virus stocks obtained from ecotropic or amophotropic and pseudotyped packaging 
cells were determined by titration on NIH/3T3 or Hela, respectively. Flow cytometric analysis 
of EGFP expression was performed to determine the titer of the viral supernatant. In brief, 
2 ´  105 cells/well were plated in 6-well tissue culture plates the nig t before infecting the cells 
with the retrovirus. The next day, cells from 3 wells were trypsinized and counted to 
 50
determine the average number of cells per well at the time of exposure to re rovirus. Serial 
dilutions (1:10) of the viral supernatant in  fi al volume of 1 ml of medium were prepared 
and added to each well in the presence of protamine sulphate (5 mg/ml). Cells were 
centrifuged at 1000 x g for 5 min at room temperature and then incubated at 37°C in 5 % CO2. 
The following day, 2.0ml of medium were added, and cells were incubated for 2 more days. 
Three days after viral infection, the transduced cells were trypsinized and resuspended in 2 ml 
of medium for flow cytometric analysis assay. Live cells were gated based on scatter/side 
scatter profile and analyzed to determine the percentage of positive cells. The titer [colony-
forming units (CFU) per ml] was calculated as:  
(% positive cells ´  cell number at initial viral exposure)/viral volume (ml) applied when 
transduction was not saturated, < 80 % (Galipeau et al., 1999).  
 
 
2.2.3.7  Flow cytometric analysis 
 
Adherent and suspension cells (105) were harvested, washed twice and resuspended in 
staining buffer (PBS plus 0.2 % BSA) in 96-well plates. Phenotypic analysis of cells was 
performed by flow cytometer (FACScalibur with CellQuest software, Becton Dickinson) 
using fluorescein isothiocyanate (FITC)- or phycoerythrin (PE)-marked mAbs in appropriate 
concentrations following the manufacturer’s instructions. Nonspecific binding was blocked by 
the addition of FcR blocking reagent (Human IgG, Miltenyi Biotec). Appropriate conjugated 
isotype-matched Abs were used as controls. To exclude dead cells, 7-amino-actinomycin D 
(7-AAD, PharMingen) was added to each sample. Ten thousand cells from each sample were 
analyzed on flow cytometer. Data presentation was performed using WinMDI version 2.8 
program.  
 
  
2.2.3.8  FLAG expression and PI-PLC release 
 
Cells transfected or transduced with pSFbS(FLAG)wDAF or pSFbS(FLAG-VLIgPl)wDAF 
retroviral vectors were washed twice and resuspended in PBS with or without 1 U/ml Bacillus 
thuringiensis phosphatidylinositol-specific phospholipase C, PI-PLC (ICN Biomedicals 
GmbH). After incubation for 60 min at 37°C, cells were analyzed for FLAG expression by 
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flow cytometer using Anti-FLAG M2 (Sigma-Aldrich Chemie GmbH). Mock-transduced 
cells were used as negative control. 
 
 
2.2.4  Immunological methods 
 
2.2.4.1  Processing and presentation of SuperAg and soluble whole Ag by PMA-derived DC 
 
To test the ability of PMA-generated DC to process and present SuperAg and soluble whole 
Ag, g-irradiated (3000 rad 137Cs) Mo or DC from day 7 PMA-treated PB-CD34+ cell cultures 
were plated in triplicate wells of 96-well flat-bottom plates (Nalge Nunc International) at        
2 ´ 104 cells/well. Purified autologous T cells (1 ´ 105 cells/ml) in complete RPMI-1640 
medium were added to the Mo- or DC-containing wells without or with 3 mg/ml 
staphylococcal enterotoxin B, SEB (Sigma-Aldrich Chemie GmbH) or 10 mg/ml preservative-
free tetanus toxoid, TT (Calbiochem-Novabiochem GmbH). Also autologous T cells were 
plated in triplicate wells of 96-well flat-bottom plates with media alone (no stimulus) or with 
media containing SEB or TT. Cultures were incubated for 7 days at 37°C in a humidified 5 % 
CO2-in-air atmosphere. T cell proliferation was assessed after 0.5 mCi/w ll [3H]-thymidine 
(Amersham Pharmacia Biotech) addition for the final 18 h of culture. Cellswere harv sted 
using a 96-well cell harvester, and [3H]-thymidine incorporation was measured using a Beta 
scintillation counter. 
 
 
2.2.4.2  Autologous T cell proliferation assay 
 
g-irradiated (3000 rad 137Cs) mock-transduced or retroviral-transduced, PMA-derived or 
cytokine-derived, DC were plated in triplicate wells of 96-well flat-bottom plates at different 
concentration. Purified autologous T cells (1 ´ 105 cells/ml) in complete RPMI-1640 medium 
were added to the DC-containing wells. Also, transduced DC or autologous T cells were 
plated in triplicate wells of 96-well flat-bottom plates with media alone as a control for assay. 
Cultures were incubated for 7 days at 37°C in a humidified 5 % CO2-in-air atmosphere. T cell 
proliferation was assessed after 0.5 mCi/well [3H]-thymidine addition for the final 18 h of 
culture. Cells were harvested using a 96-well cell harvester, and [3H]-thymidine incorporation 
was measured using a Beta scintillation counter. Proliferative index (PI) value was calculated 
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as the ratio between the mean CPM of T cells in the presence and in the absence of transduced 
DC in the cultures. 
 
 
2.2.4.3  MHC restriction of T cell response 
 
To study MHC restriction of T cell response, antibodies against MHC class I (HLA-ABC, 
clone B9.12.1, Immunotech GmbH), class II (HLA-DR, clone B8.12.2, Immunotech GmbH), 
or an isotypic control mouse IgG at 20 mg/ml were added to the cultures at the initiation of the 
autologous proliferation assay.   
 
2.2.4.4  Inhibitory effect of CD86 antibodies on T cell respons 
 
To study the role of CD86 (B7-2) co-stimulatory molecule in T cell activation, antibodies 
against CD86 (clone IT2.2, PharMingen GmbH) or an isotypic control mouse IgG at 20 mg/ml 
were added to the cultures at the initiation of the autologous proliferation assay.   
 
 
2.2.5  Statistical analysis 
 
Data are presented as mean values ± SD. For comparison of two groups, unpaired t tests and 
Mann-Whitney test (U-test) were used. For comparison of three or more groups, Ordinary 
one-way ANOVA and Kruskal-Wallis test were used. P values of < 0.05, < 0.01 and < 0.001 
were considered statistically significant, highly significant and very highly significant, 
respectively. 
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3  Results 
 
 
3.1  VL gene usage by tumor cells 
 
In order to amplify tumor specific transcripts of the variable region of paraprotein light chain 
(VL), reverse transcriptase-polymerase chain reaction (RT-PCR) of total RNA isolated from 
mononuclear cells (MNC) of heparinized bone marrow aspirate of a plasmocytoma patient 
(E.G) was performed. 
 
Figure 7 shows that 2 to 40 mg of total RNA were isolated from 0.1-2 ´ 07 MNC fraction of 
the plasmocytoma patient. The final preparation of RNA was free of DNA and protein 
contamination and had a 260/280 ratio higher than 1.8. RT-PCR was carried out using a 
mixture of 5' oligonucleotide FWR1 primers specific for the expressed V or V  families 
together with a mixture of downstream 3' primers specific for J or J  genes (Sahota et al., 
1997). The size of the amplified plasmocytoma v riable region of immunoglobulin light chain 
(VLIgPl) was about 350 pb (Figure 8). 
 
The VLIgPl used by the tumor cells was identified as repeated id ntical VL-JL sequences 
obtained after cloning of PCR products (Figure 9). Non-identical sequences were presumably 
from normal plasma cells in the aspirate (Hawkins et al., 1994; Sahota et al., 1997). 
Sequencing alignment was made to current EMBL/GenBank and V-BASE sequence 
directories (Cook and Tomlinson, 1995) using MacVector 4.0 sequence analysis software 
(International Biotechnologies Inc). Sequence analysis of VLIg of the plasmocytoma patient 
revealed a V segment of the VkIV subgroup (Figure 10).
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Lanes Number of MNC Total RNA Purity % 
1 2 ´  107 40 mg 1.8 
2 1 ´  107 13 mg 1.84 
3 5 ´  106 8 mg 1.9 
4 2 ´  106 3.5 mg 1.87 
5 1 ´  106 2 mg 1.82 
 
Figure 7: Total RNA isolation from different cell numbers of MNC of heparinized bone 
marrow aspirate of a plasmocytoma patient (E.G). 
 
 
 
 
Figure 8: VLIgPl RT-PCR. Lane 1, 100 bp DNA Ladder; lane 2-5, four independent PCR 
amplifications and lane 6, negative control. 
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Alignment for V segment 
                                                        
           1   2   3   4   5   6   7   8   9   10  11  12  13  14  15  16  17  18  19  20  21   
2YP999     GAC ATC GTG ATG ACC CAG TCT CCA GAC TCC CTG GCT GTG TCT CTG GGC GAG A GG GCC ACC ATC  
7YP999     ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  
8YP999     ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  
9YP999     ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  
1YP999     ---  ---  - A-  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  
4YP999     ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  
10YP999    ---  ---  -- -  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  
5YP999     ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  
 
                           _____________________________L1____________________                  
                   ____________________________________CDR1___________________________          
           22  23  24  25  26  27  28  29  30  31  31a 31b 31c 31d 31e 31f 32  33  34  35  36   
2YP999     AAC TGC AAG TCC AGC CAG AGT GTT TTA TAC AGC  TCC AAC AAT AAG AAC TAC TTA GCT TGG TAC  
7YP999     ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  
8YP999     ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  
9YP999     ---  ---  ---  - --  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  
1YP999     ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  
4YP999     ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  - G-  ---  ---  ---  ---  ---  ---  
10YP999    ---  ---  ---  ---  ---  ---  ---  ---  ---  - K-  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  
5YP999     ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  
 
                                                               _____L2____                      
                                                               ____________CDR2___________      
           37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57   
2YP999     CAG CAG AAA CCA G GA CAG CCT CCT AAG CTG CTC ATT TAC TGG GCA TCT ACC CGG GAA TCC GGG  
7YP999     ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  
8YP999     ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  -- -  
9YP999     ---  ---  ---  ---  ---  ---  ---  - Y-  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  
1YP999     ---  ---  ---  ---  ---  ---  ---  - T-  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  
4YP999     ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  - --  ---  ---  ---  ---  ---  ---  ---  
10YP999    ---  ---  ---  ---  -- R ---  ---  - S-  ---  ---  M--  ---  ---  ---  ---  -- W ---  ---  ---  ---  ---  
5YP999     ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  
                                                                                         
           58  59  60  61  62  63  64  65  66  67  68  69  70  71  72  73  74  75  76  77  78   
2YP999     GTC CCT GAC CGA TTC AGT GGC AGC GGG TCT GGG ACA GAT TTC ACT CTC ACC ATC AGC AGC CTG  
7YP999     ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  
8YP999     ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  
9YP999     ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  - --  ---  ---  ---  ---  
1YP999     ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  
4YP999     ---  ---  ---  ---  ---  ---  ---  ---  - K-  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  
10YP999    ---  ---  ---  ---  ---  ---  ---  ---  ---  - M-  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  
5YP999     ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  
 
                                                           _________L3________  
                                                   ____________________CDR3____  
           79  80  81  82  83  84  85  86  87  88  89  90  91  92  93  94  95   
2YP999     CAG GCT GAA GAT GTG GCA GTT TAT TAC TGT CAG CAA TAT TAT AGT ACT CCT  
7YP999     ---  ---  ---  ---  ---  ---  ---  ---  ---  - --  ---  ---  ---  ---  ---  ---  ---  
8YP999     ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  
9YP999     ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  
1YP999     ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  
4YP999     ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  
10YP999    ---  S --  ---  ---  ---  ---  ---  ---  - M-  ---  ---  ---  ---  ---  ---  ---  ---  
5YP999     ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  - T-  ---  -- C 
 
Alignment for J segment 
 
2YP999     TGTCAGCAATATTATAGTACTCCTCGGGGGCCACCTTCGGCCAAGGGACACGACTGGAGATTAAACGT 
7YP999     --------------------------------------------------------------------  
8YP999     ------------------------------------------------------------------ --  
9YP999     --------------------------------------------------------------------  
1YP999     ---------------------------------- . ---------------------------------  
4YP999     --------------------------------------------------------------------  
10YP999    -- ------------------------------------------------------------------  
5YP999     ---------------- T------ CACTTTCGGCGGAGG- A---- A- TGG- AAT- AAAC- T........  
 
 
Figure 9: Repeated identical VL-J L sequences of a plasmocytoma patient. Dashes indicate 
sequence identity, and points indicate loss of nucleotides. K = g + t, M = a + c, R = a + g,        
S = c + g, W = a + t, Y = c + t. 
 
 Alignment for V segment                 
                                          1   2   3   4   5   6   7   8   9   10  11  12  13  14  1 5  16  17  18  19  20  21   
EMBL    Locus        VLIgPl                 GAC ATC GTG ATG ACC CAG TCT CCA GAC TCC CTG GCT GTG TCT CTG GGC GAG AGG GCC ACC ATC 
X93640  B3           DPK24/VkIVKlob...+   ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  -- -  ---  ---  ---  ---  ---  ---   
X72815  L16          L16/humkv31es...+    -- A -- A ---  ---  -- G ---  ---  ---  - C-  A --  ---  T --  ---  ---  - CA -- G -- A -- A ---  ---  C --   
X93638  L2           DPK21/humkv328h5+    -- A -- A ---  ---  -- G ---  ---  ---  - C-  A --  ---  T --  ---  ---  - CA -- G -- A -- A ---  ---  C --   
Z27500  L25/Orphon   DPK23/L25...+        -- A -- T -- A ---  -- A ---  ---  ---  - C-  A --  ---  T --  T --  ---  - CA -- G -- A -- A ---  ---  C --   
M23091  L16          humkv329+            -- A -- A ---  ---  - TG ---  ---  ---  - C-  A --  ---  T --  ---  ---  - CA -- G -- A -- A ---  ---  C --   
                                                          _____________________________L1____________________                  
                                                  ____________________________________CDR1________________ ___________          
                                          22  23  24  25  26  27  28  29  30  31  31a 31b 31c 31d 31e 31f 32  33  34  35  36   
EMBL    Locus        VLIgPl                 AAC TGC AAG TCC AGC CAG AGT GTT TTA TAC AGC TCC AAC AAT AAG AAC T AC TTA GCT TGG TAC  
X93640  B3           DPK24/VkIVKlob...+   ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---   
X72815  L16          L16/humkv31es...+    TC -  ---  - G-  G--  -- T ---  ---  ---  AGC AG-  ... ... ... ... ... ... A --  ---  -- C ---  ---   
X93638  L2           DPK21/humkv328h5+    TC -  ---  - G-  G--  -- T ---  ---  ---  AGC AG-  ... ... ... ... ... ... A --  ---  -- C ---  ---   
Z27500  L25 /Orphon    DPK23/L25...+        TC -  ---  - G-  G--  -- T ---  ---  ---  AGC AG-  ---  ... ... ... ... ... ---  - --  T - C ---  ---   
M23091  L16          humkv329+            TC -  ---  - G-  G--  -- T ---  ---  ---  AGC AG-  ... ... ... ... ... ... A --  ---  -- C ---  ---   
                                                                                              _____L2____                      
                                                                                              ____________CDR2___________      
                                          37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  5 5  56  57   
EMBL    Locus        VLIgPl                 CAG CAG AAA CCA GGA CAG CCT CCT AAG CTG CTC ATT TAC TGG GCA TCT ACC CGG GAA TCC GGG  
X93640  B3           DPK24/VkIVKlob...+   ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  -- -  ---  ---   
X72815  L16          L16/humkv31es...+    ---  ---  ---  -- T -- C ---  G--  -- C - G-  -- C ---  -- C -- T G- T ---  -- C ---  A --  - CC A- T -- C  
X93638  L2           DPK21/humkv328h5+    ---  ---  ---  -- T -- C ---  G--  -- C - G-  -- C ---  -- C -- T G- T ---  -- C ---  A --  - CC A- T -- T  
Z27500  L25 /Orphon    DPK23/L25...+        ---  ---  ---  -- T -- G ---  G--  -- C - G-  -- C ---  -- C -- T G- T ---  -- C ---  A --  - CC A- T -- C  
M23091  L16          humkv329+            ---  ---  ---  -- T -- C ---  G--  -- C - G-  -- C ---  -- C -- T G- T ---  -- C ---  A --  - CC A- T -- C  
                                                                                                                               
                                          58  59  60  61  62  63  64  65  66  67  68  69  70  71  72  73  74  75  76  77  78   
EMBL    Locus        VLIgPl                 GTC CCT GAC CGA TTC AGT GGC AGC GGG TCT GGG ACA GAT TTC ACT CTC ACC ATC AGC AGC CTG  
X93640  B3           DPK24/VkIVKlob...+   ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---  - --   
X72815  L16          L16/humkv31es...+    A --  -- A - C-  A - G ---  ---  ---  -- T ---  ---  ---  ---  -- G ---  ---  ---  ---  ---  ---  ---  ---   
X93638  L2           DPK21/humkv328h5+    A --  -- A - C-  A - G ---  ---  ---  -- T ---  ---  ---  ---  -- G ---  ---  ---  ---  ---  ---  ---  ---   
Z27500  L25/Orphon   DPK23/L25...+        A --  -- A - C-  A - G ---  ---  ---  -- T ---  ---  ---  ---  -- C ---  ---  ---  ---  ---  ---  ---  ---   
M23091  L16          humkv329+            A --  -- A - C-  A - G ---  ---  ---  -- T ---  ---  ---  ---  -- G ---  ---  ---  ---  ---  ---  ---  ---   
                                                                                          _________L3________  
                                                                                  ____________________CDR3____  
                                          79  80  81  82  83  84  85  86  87  88  89  90  91  92  93  94  95   
EMBL    Locus        VLIgPl                 CAG GCT GAA GAT GTG GCA GTT TAT TAC TGT CAG CAA TAT TAT  AGT ACT CCT  
X93640  B3           DPK24/VkIVKlob...+   ---  ---  ---  ---  ---  ---  - --  ---  ---  ---  ---  ---  ---  ---  ---  ---  ---   
X72815  L16          L16/humkv31es...+    ---  T --  ---  ---  T - T ---  ---  ---  ---  ---  ---  -- G ---  A --  - AC TGG ---   
X93638  L2           DPK21/humkv328h5+    ---  T --  ---  ---  T - T ---  ---  ---  ---  ---  ---  -- G ---  A --  - AC TGG ---   
Z27500  L25 /Orphon    DPK23/L25...+        ---  C --  ---  ---  T - T ---  ---  ---  ---  ---  ---  -- G G--  ---  - AC TTA ---   
M23091  L16          humkv329+            ---  T --  ---  ---  T - T ---  ---  ---  ---  ---  ---  -- G ---  A --  - AC TGA ---   
 
The sequence uses a V s egment of the V KIV  subgroup.  
 
Figure 10: Sequence analysis of VLIg gene expressed in a plasmocytoma patient (VLIgPl). Dashes indicate sequence identity, and points indicate 
loss of nucleotides. Analysis performed by DNAPLOT Version 2.0.1 using V BASE Version 1.0. 56 
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3.2  Retroviral expression-cloning vectors 
 
The most widely used retroviral vectors contain an antibiotic-resis ance gene such as 
neomycin (NeoR) that is strongly immunogenic. Its peptides will be presented on MHC class I 
molecules and activate CD8+ T lymphocytes, thus skewing the elicited immune response. To 
avoid this, a novel retroviral expression-cloning vector that directs the tumor-associated 
antigen of plasmocytoma marked with a FLAG antibody-bi d ng site to the plasma membrane 
via a glycosylphosphatidylinositol (GPI)-anchor has been constructed. Thus, transfected or 
transduced cells can be detected using monoclonal anti-FLAG antibodies.  
 
The GPI-anchored construct has been chosen because of its stable transgene surface 
expression without a m jor dependence on the transcription rate, which is limiting for 
constructs using nerve growth factor receptor (NGFR) or epidermal growth factor (EGF) 
fusion peptides (Austin et al., 2000). For targeting the transgene to a GPI-linked protein, a 
GPI-linked protein that is endogenously expressed in DC such as decay-accelerating factor 
(DAF) has been used in order to avoid an imbalance of presentation of foreign peptides apart 
from VLIgPl. 
 
 
3.2.1  Retroviral vectors construction 
 
3.2.1.1  pSFbS(FLAG-VLIgPl)wDAF  
 
The novel retroviral vector pSFbS(FLAG-VLIgPl)wDAF has been constructed as follows: 
 
A) Construction of plasmid Bluescript SK(+) containing the FLAG sequence in frame 
between the two hydrophobic ends of DAF: 
The SacI NotI Start-codon NH2(34a.a)DAF FLAG XbaI in frame has been constructed 
from pSPORT1 contained 5' end of DAF and transformed in DH10B (clone DKFZp434P184) 
by PCR using SacI NotI Start Signal sense primer and XbaI FLAG Signal anti-sense primer 
and was inserted into pBluescript SK(+) by NotI and XbaI digestion. In addition, the XbaI 
ClaI DAF(37a.a)COOH Stop-codon HindIII KpnI in frame has been constructed from 
pT7T3D-PAC mod1 contained 3' end of DAF and transformed in DH10B (clone 
IMAGp998D23661) by PCR using XbaI ClaI GPI sense primer and KpnI HindIII Stop GPI 
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anti-sense primer and was inserted into the above pBluescript SK(+) containing NotI Start-
codon NH2(34a.a)DAF FLAG XbaI in frame by XbaI and KpnI digestion (Figure 11A). 
 
B) Construction of plasmid Bluescript SK(+) containing the FLAG-VLIgPl in frame between 
the two hydrophobic ends of DAF: 
The XbaI VLIgPl ClaI in frame has been constructed by PCR using XbaI 2YP999 sense 
primer and ClaI 2YP999 anti-sense primer and was inserted into the above pBluescript SK(+) 
containig NotI Start-codon NH2(34a.a)DAF FLAG XbaI ClaI DAF(37a.a)COOH Stop-
codon HindIII KpnI in frame by XbaI and ClaI digestion (Figure 11B). 
 
C) Construction of the retroviral vector that directs the FLAG-VLIgPl fusion protein to the 
plasma membrane via GPI-anchor: 
The novel retroviral vector pSFbS(FLAG-VLIgPl)wDAF has been constructed by replacing the 
NeoR (neomycin resistance) fragment of pSFbN1, kindly provided by Dr. Christopher Baum 
(Baum et al., 1995) with NotI Start-codon NH2(34a.a)DAF FLAG XbaI VLIgPl ClaI 
DAF(37a.a)COOH Stop-codon HindIII  by NotI and HindIII digestion (Figure 11C). 
 
 
3.2.1.2  pSFbS(FLAG)wDAF 
 
The vector pSFbS(FLAG)wDAF without the VLIgPl has been constructed by replacing the 
NeoR (neomycin resistance) fragment of pSFbN1 with NotI Start-codon NH2(34a.a)DAF 
FLAG XbaI ClaI DAF(37a.a)COOH Stop-codon HindIII  by NotI and HindIII digestion. 
 
 
3.2.1.3  pSFbEGFP 
 
The NeoR of pSFbN1 was replaced by enhanced green fluorescent protein gene (EGFP), 
isolated as a 763-bp fragment from pBI-EGFP plasmid by NotI and HindIII digestion, to 
generate pSFbEGFP used as control for transfection and transduction efficacy. 
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Figure 11: Steps of the pSFbS(FLAG-VLIgPl)wDAF retroviral vector construction:              
(A) Construction of plasmid Bluescript SK(+) containing the FLAG in frame between the two 
hydrophobic ends of DAF, (B) Construction of plasmid Bluescript SK(+) containing the 
FLAG-VLIgPl in frame between the two hydrophobic ends of DAF and (C) Construction of the 
retroviral vector that directs the FLAG-VLIgPl fusion protein to the plasma membrane via 
GPI-anchor. 3' HR, 3' hydrophobic region of DAF; 5' HR, 5' hydrophobic region f DAF; 
LTR, long terminal repeat; MESV, murine embryonic stem cell virus; PCMV, PCC4-cell-
passaged mutant virus; SFFVp, polycythemic strain of the spleen focus-forming vir  and y, 
indicates the presence of retroviral packaging sequence. 
(A) 
(B) 
(C) 
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The objective of this work was to induce efficient transfer and expression of VLIgPl ge e in 
DC. Therefore, the SFFVp/MESV hybrid retroviral vector backbone has been chosen, which 
was designed to overcome transcriptional inefficiency and silencing associated with retroviral 
gene transfer into myeloid progenitors and haematopoietic stem cells (Baum t al., 1995).  
 
Figure 12 demonstrates the schematic diagram of the retroviral vectors pSFbS(FLAG-
VLIgPl)wDAF, pSFbS(FLAG)wDAF and pSFbEGFP. The novel retroviral vector, 
pSFbS(FLAG-VLIgPl)wDAF, contains FLAG-VLIgPl fusion protein in frame between the two 
ends of DAF. The first 34 and the last 37 amino acids of DAF are hydrophobic domains 
cleaved upon attachment to the GPI-anchor molecule (Moran et al., 1991). In addition, the 
cleavage attachment site (w) is located within the carboxyterminus leading to GPI-linked 
transgene expression provided by this vector (Figure 13). The GPI-anchor contains 
phosphatidylinositol, carbohydrate and ethanolamine d is though to be preassembeld in the 
endoplasmic reticulum (Masterson et al., 1989; Udenfriend and Kodukula, 1995; Kinoshita 
and Inoue, 2000). Anchor addition apparently takes place in the endoplasmic reticulum 
(Bangs et al., 1985, 1986; Ferguson et al., 1986; Udenfriend and Kodukula, 1995; Kinoshita 
and Inoue, 2000), after which the protein is transported to the cell surface via the Golgi 
apparatus (Caras, 1991). Xba1 and Cla1 restriction sites are not p sent in any type of human 
V genes. Thus, any type of the VLIg after Xba1 and Cla1 restriction sites addition can be 
directly cloned into this novel retroviral expression-cloning vector in order to obtain the 
segment of interest in frame with the recognition sequences of DAF. As a result, the vector 
pSFbS(FLAG)wDAF without the VLIgPl directs the FLAG to the plasma membrane and can 
be used as a control for immune response. 
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Figure 12: Schematic diagram of the retrovi al vectors pSFbS(FLAG-VLIgPl)wDAF, 
pSFbS(FLAG)wDAF and pSFbEGFP. LTR, long terminal repeat; MESV, murine embryonic 
stem cell virus; PCMV, PCC4-cell-passaged mutant virus; SFFVp, polycythemic strain of the 
spleen focus-forming virus and y, indicates the presence of retroviral packaging sequence. 
 
 
 
 
Figure 13: Schematic diagram of the GPI attachment to the FLAG-VLIgPl fusion protein. 
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3.2.2  Testing the novel retroviral vector through transient expression of FLAG in 
Jurkat cells  
 
Jurkat wild type cells were transfected with pSFbS(FLAG-VLIgPl)wDAF retroviral vector via 
electroporation to make sure that it targets the FLAG-VLIgPl fusion protein to the cell surface. 
Different electroporation protocols were carried out to determine th  optimal transfection 
conditions. The best result (13.2 %) obtained at higher cells number (2 ´ 107) in a final 
volume of 500 µl medium containing 40 mg retroviral vector at 350 V, 1050 mF and RT  
(Table 2).  
 
Cell 
number 
DNA 
amount 
Final 
volume 
Voltage Capacity Temperature 
FLAG  
expression 
1 ´  106 10 mg 1000 ml 250 V 800 mF 4°C 0.93 % 
1 ´  106 10 mg 1000 ml 250 V 800 mF RT 1.36 % 
5 ´  106 20 mg 800 ml 250 V 800 mF 4°C 4.99 % 
5 ´  106 20 mg 800 ml 250 V 800 mF RT 5.5 % 
1 ´  107 30 mg 800 ml 250 V 800 mF 4°C 6.8 % 
1 ´  107 30 mg 800 ml 250 V 800 mF RT 7 % 
2 ´  107 40 mg 800 ml 350 V 1050 mF 4°C 10.3 % 
2 ´  107 40 mg 500 ml 350 V 1050 mF RT 13.2 % 
  
Table 2: FLAG expression in Jurkat wild type cells transfected with pSFbS(FLAG-
VLIgPl)wDAF retroviral vector via different electroporation protocols. RT: room temperature.
 
In order to verify GPI-anchoring of the transgene, phosphatidylinositol-specific  
phospholipase C (PI-PLC) was used that specifically releases proteins bound to the membrane 
via GPI-anchor (Moran et al., 1991). As shown in Figure 14, FLAG signals from transfected 
cells could be released by PI-PLC indicating that the retroviral vector targets the fusion 
protein to the cell surface via GPI-anchor.  
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Figure 14: PI-PLC dependent release of cell surface FLAG of transfected Jurkat wild type 
cells with pSFbS(FLAG-VLIgPl)wDAF indicating that this retroviral vector targets the fusion 
protein to the cell surface via GPI- nchor. Transfected cells treated with or without PI- LC 
are indicated by dotted and solid lines, respectively. Shaded areas represent the non-
transfected cells. M2: Anti-FLAG antibody-binding. 
 
 
3.3  Serum-free culture conditions for in vitro generation of dendritic cells 
 
The identification of culture conditions enabling the generation of DC n vitroare useful to 
study their biology and to prepare large amounts of APC for immunotherapeutic purposes 
(Ferlazzo et al., 1999). It is now known that CD34-derived dendritic cells (CD34-DC) have a 
preferential capacity to activate CD8+ T cells (Ferlazzo et al., 1999) and CD86 is the most 
important ligand to induce CD28-mediated co-stimulation for CD8+ T cell activation (Van 
Gool et al., 1999). DC can be generated in vitro from CD34+ progenitors in cord blood [CB] 
(Santiago-Schwarz et al., 1992; Sato et al., 1998), bone marrow [BM] (Reid et al., 1992; 
Szabolcs et al., 1995) and peripheral blood [PB] after cytokine mobilization (Strunk et al., 
1996; Ratta et al., 1998). However, the cytokine requirements to differentiate CB- and      
PB-CD34+ progenitor cells into DC are known to be different (Garb  t al., 1998). GM-CSF 
plus TNF-a ± SCF used in most protocols described not only for generation of DC but also of 
macrophages and neutrophils (Santiago-Schwarz et al., 1992; Szabolcs et al., 1995; Bender  
et al., 1996). In addition, FCS used as culture supplement in most of the protocols described 
contains additional foreign antigens leading to potential skewing of the resulting immune 
response.  
 
Phorbol ester (PMA) is a stable analogue of 2,3-diacylglycerol that activates the classical (a, 
b1, b2 and g) and new (d, e, h, q and m) isoforms of protein kinase C [PKC] (Nishizuka, 
13.2 % 
E
v
e
n
ts 
M2 
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1995). PMA-mediated signaling induced the expression of the RelB transcription factor, 
suggesting a pathway by which genetic events involved in DC differentiation are initiated 
(Davis et al., 1998). Recently, it was reported that PMA-induced PKC activation specifically 
leads to differentiation of bone marrow CD34+ progenitor cells to mature DC in serum-
containing medium and no other lineages are generated (Davis et al., 1998; St. Louis et al., 
1999). Here the ability to differentiate CD34+ progenitor cells from different origins into DC 
under serum-free conditions in the presence of PMA was studied. 
 
 
3.3.1  Ex vivo expansion of CD34+ progenitors under serum-free conditions  
 
Ex vivo expansion of CD34+ progenitor cells facilitates the identification of culture conditions 
useful to generate DC to study their biology and retroviral transduction for 
immunotherapeutic purposes (Glimm et al., 198). To test the ability to expand CD34+ 
progenitor cells under serum-free conditions, the increase in cell counts of BM-CD34+ cells 
cultured in complete serum-containing medium IMDM or RPMI-1640 was compared with 
that cultured in complete serum-fr e edium CellGroÒ SCGM or CellGroÒ DC containing 
either Flt-3L, 150 ng/ml; IL-3, 100 ng/ml; SCF, 50 ng/ml and TGF-b1, 0.5 ng/ml or Flt-3L, 
300 ng/ml; IL-3, 100 ng/ml and SCF, 100 ng/ml (Table 3).  
 
Expansion (fold) 
Complete serum-containing media Complete serum-free media 
IMDM  RPMI -1640 CellGroÒ SCGM CellGroÒ DC 
 
 
 
 
 
 
 
Experiment 
1st 
cytokine 
cocktail 
2nd 
cytokine 
cocktail  
1st 
cytokine 
cocktail 
2nd 
cytokine 
cocktail 
1st 
cytokine 
cocktail 
2nd 
cytokine 
cocktail 
1st 
cytokine 
cocktail 
2nd 
cytokine 
cocktail 
1 3.16 4.35 3.00 4.36 2.90 4.70 2.40 3.30 
2 3.55 4.80 3.70 4.50 3.90 5.50 3.10 3.39 
3 4.19 5.11 3.77 5.21 4.21 4.94 3.60 3.90 
Mean ± SD 3.63 ± 0.52 4.75 ± 0.38 3.49 ± 0.43 4.69 ± 0.46 3.67 ± 0.68 5.05 ± 0.41 3.03 ± 0.60 3.53 ± 0.32 
 
Table 3: Expansion ofBM-CD34+ cells in serum-free media compared with serum-containing 
media and with different cytokine cocktails. BM-CD34+ cells (5 ´ 104 cells/ml) cultured in 
complete serum-containing medium IMDM or RPMI-1640 or complete serum-f ee medium 
CellGroÒ SCGM or CellGroÒ DC containing either 1st cytokine cocktail (Flt-3L,                
150 ng/ml; IL-3, 100 ng/ml; SCF, 50 ng/ml and TGF-b1, 0.5 ng/ml) or 2nd cytokine cocktail 
(Flt-3L, 300 ng/ml; IL-3, 100 ng/ml and SCF, 100 ng/ml). Cultures were incubated for 7 days 
at 37°C and 5 % CO2.  
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Figure 15A shows that there is no statistical difference (P = 0.344, n = 12) in expansion 
between serum-containing media and serum-free media. The highest (4.36 ± 0.91, n = 6) and 
lowest (3.28 ± 0.51, n = 6) expansions were in CellGroÒ SCGM and CellGroÒ DC, 
respectively (Figure 15B). The expansion using cytokine cocktail 2 is significantly better       
(P = 0.0005, n = 12) than that using cytokine cocktail 1 (Figure 15C). Thes findings 
demonstrate that the best conditions for expansi n of CD34+ cells are provided in serum-free 
medium (CellGroÒ SCGM) containing Flt-3L (300 ng/ml), IL-3 (100 ng/ml) and SCF       
(100 ng/ml). In the case that 50 % of the cytokine-con aining medium was exchanged after    
3 days and the density of cells did not exceed 105 cells/ml, the increase of cells was 18.5-fold. 
Therefore, the above cytokine cocktail facilitates retroviral transduction. 
 
 
 
Figure 15: Effect of (A) serum (B) different media and (C) different cytokine cocktails on     
in vitro expansion of CD34+ progenitor cells.  
a Unpaired t-tests     
b Ordinary one-way ANOVA     
*** Very highly significant 
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3.3.2  PMA-derived dendritic cells 
 
3.3.2.1  Phorbol ester induces differentiation of CD34+ progenitors from different origins to 
DC under serum-free conditions  
 
For DC generation out of CD34+ cells by cytokine cocktails, large amounts of cytokines are 
necessary. In addition, cells generated by such cytokine cocktails are not only confined to the 
DC monocytic lineage. In order to analyze DC function in Ag presentation of VLIgPl 
peptides, a more homogeneous DC fraction is needed. Therefore, PMA was used, which has 
the capability to trigger DC differentiation out of BM derived CD34+ cells without 
contamination with other cell lineages. Here, the ability of PMA to differentiate CB- and    
PB-CD34+ progenitor cells to DC using serum-free conditions has been examined.  
 
By day 7, about 40-60 % of CB- and PB-CD34+ progenitor cells cultured in serum-fr e 
medium (CellGroÒ DC) with 15 ng/ml PMA became large and loosely adherent and a subset 
developed long dendrites and hair-like cytoplasmic projections (Figure 16), a morphology 
reported to be characteristic of DC (Hart, 1997). Morphologic changes were presnt within 
one day of stimulation and completed within three days. They were stable over at least            
2 weeks in culture.  
 
Expression of the co-stimulatory molecule CD86 (B7-2), and the DC lineage marker CD83 
typically characterize mature DC. Phenotypic analysis at day 7 after PMA-induction of CB- 
and PB-CD34+ progenitor cells (adherent and non-a herent) demonstrated that all cells were 
positive for both CD83 and CD86 and negative for CD1a (Figure 17). In addition these cells 
were CD1a- throughout all experiments. These data are in accordance with the finding that 
PMA induces DC differentiation without causing cell proliferation and the generation of 
cellular intermediates (Davis et al., 1998).  
 
 
 
 
 
 
 
 67
 
CB                                             PB
    
 
Figure 16: Typical morphology of cord blood (CB)- and cytokine mobilized peripheral blood 
(PB)-CD34+ cells cultured in serum-free medium (CellGroÒ DC) upon stimulation with PMA 
alone for 7 days (arrows indicate elongated dendrites).  
 
 
 
 
Figure 17: Surface Ag phenotype characterization of day 7 PMA-treated cord blood (CB)- 
and cytokine mobilized peripheral blood (PB)-CD34+ cell cultures in serum-free medium. 
Total cells in cultures (adherent and non-adherent) were analyzed by flow cytometric 
analysis. Isotype-matched controls are indicated by dotted lines. Results are representative of 
three different experiments.  
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3.3.2.2  Phorbol ester induces differentiation of ex vivo expanded CD34+ progenitors to DC in 
serum-free medium 
 
Murine oncoretroviral vectors require cell division for integration into the nucleus. Therefore, 
a round of expansion of CD34+ cells is required before their differentiation into DC in the 
presence of PMA. The efficien y of DC differentiation by PMA after expansion of        
CD34+ cells needs to be investigated.  
 
To test if morphological and phenotypic changes induced by PMA were affected by 
pretreatment of BM-CD34+ cells with a cytokine cocktail that induced a large expansion 
under serum-free conditions, the cells were expanded for 7 days in CellGroÒ SCGM 
containing Flt-3L (300 ng/ml), IL-3 (100 ng/ml) and SCF (100 ng/ml) and then differentiated 
in CellGroÒ DC containing 15 ng/ml PMA until day 14. 
 
Figure 18 shows that the DC differentiation induced by PMA under serum-free conditions 
was not affected morphologically by pretreatment of BM-CD34+ cells with the above 
cytokine cocktail that induced CD34+ cell expansion connected with myeloid, but not with 
DC differentiation, as described previously (Davis et al., 1998). In addition, the cells were 
positive for CD83 and CD86 and negative for CD1a and CD14 (Figure 19). Table 4 
demonstrates that at day 14, 2.94 ± 0.42-fold increase of the cell number was obtained. 
Because the used cytokines facilitate murin  oncoretroviral tr nsduction (Glimm et al., 1998), 
the method described in this study may be used preferentially for introducing genes into DC 
by retroviral vectors. 
 
             
3.3.2.3  CD86+ yield of PMA-derived DC compared with that of cytokine-derived DC under 
serum-free conditions 
 
To study the efficacy of PMA to generate mature DC in serum-free medium, PMA-derived 
DC were compared with cytokine-derived DC using the same serum-fr e culture conditions. 
The maturation of cultured human blood DC was delineated by surface analysis of the co-
stimulatory molecule B7-2 (CD86), because it is the most important ligand to induce CD28-
mediated co-stimulation for CD8+ T cell activation (Van Gool et al., 1999). 
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   Before expansion                     After expansion                  After differentiation 
    
                 (Day 0)                                     (Day 7)                                     (Day 14) 
 
Figure 18: Morphology of PMA-derived DC from ex vivo expanded BM-CD34+ progenitor 
cells (arrow indicates elongated dendrite). 
 
 
 
        
 
Figure 19: Surface Ag phenotype characterization of day 7 PMA-derived DC from ex vivo 
expanded BM-CD34+ progenitor cells. 
 
 
 
 Cell number 
Experiment After expansion 
(Day 7) 
After differentiation 
(Day 14) 
1 2.35 ´ 105 (4.70) 1.48 ´ 105 (2.96) 
2 2.80 ´ 105 (5.60) 1.80 ´ 105 (3.60) 
3 2.24 ´ 105 (4.48) 1.28 ´ 105 (2.56) 
4 2.05 ´ 105 (4.10) 1.29 ´ 105 (2.57) 
5 2.59 ´ 105 (5.18) 1.50 ´ 105 (3.00) 
Mean ± SD (4.81 ± 0.59) (2.94 ± 0.42) 
 
Table 4: Viable cell counts of BM-CD34+ cells after expansion and differentiation for one 
week with PMA under serum-f ee conditions. The data enclosed in brackets represent the fold 
increase in cell number.  
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CD86+ yield was calculated as the ratio of the output number of CD86+DC relative to the 
input number of CD34+ progenitor cells with the following equation:  
CD86+ yield = Number of viable CD86+DC at the end of experiment ´ 100 / the input number 
of CD34+ progenitor cells (5 ´ 104) 
 
In case of a shift, as found in PMA-induced DC, all cells have been considered to be positive. 
In contrast, CD86+ and CD86- cells in cytokine-induced DC have been separable because not 
all cells shifted towards a positive CD86-expression. In this case only positive cells have been 
considered as induced DC (Figure 20).  
 
                            Cytokine-derived DC                              PMA-derived DC 
 
 
Figure 20: CD86 expression in cytokine- and PMA-derived DC. Isotype-matched controls are 
indicated by dotted lines.  
 
It is well known that the cytokine requirements to differentiate CB- and PB-CD34+ progenitor 
cells into DC are different (Garbe et al., 1998). Therefore, CD34+ progenitors from CB and 
PB in parallel experiments were used for this experiment.  
 
CD86+ yield was 28.0 % ± 7.0 and 44.6 % ± 7.5 for CB- and PB-derived dendritic cells upon 
stimulation with PMA for one week in serum-fr e edium (CellGroÒ DC), respectively 
(Figure 21). In contrast, the yield was 15.3 % ± 5.6 and 28.1 % ± 7.5 for CB- and PB-derived 
DC stimulated with different cytokine cocktails specifically for CB and PB differentiation, 
respectively, and for indicated periods of time in the same serum-free medi m as mentioned 
in material and methods. These data suggest that under serum-free conditions CD86+ yield 
was increased by PMA compared to cytokine cocktails. 
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Figure 21: CD86+ yield of CB- and PB-derived endritic cells stimulated with PMA for one 
week or with different cytokine cocktails specifically for CB and PB in serum-free medium 
(CellGroÒ DC) and for indicated periods of time as mentioned in material and methods. CB, 
cord blood; PB, cytokine mobilized peripheral blood. 
1 Number of viable CD86+DC at the end of experiment ´ 100 / 5 ´ 104  
* Significant, P < 0.05, Mann-Whitney test (U-test)  
 
 
 
 
 
Figure 22: CD86+ expression of PB-derived dendritic cells after one week stimulation with 
serum-free medium (CellGroÒ DC) containing PMA alone or plus TNF-a or ionomycin. 
Isotype-matched controls are indicated by dotted lines. Results are representative of three 
different experiments.  
1 Mean fluorescence  
* Significant, P < 0.05, Kruskal-Wallis test  
 
 72
3.3.2.4  Effect of addition TNF-a or ionomycin to the serum-f ee medium containing PMA on 
the output number of viable cells and CD86+ expression of the CD34+-derived dendritic cells 
 
PB-CD34+ cells were also stimulated with PMA plus 10 ng/ml TNF-a or plus 100 ng/ml 
ionomycin in complete serum-free medium (CellGroÒ DC) for 7 days to study their effect on 
PMA-derived DC.  
 
Figure 22 demonstrates that up-regulation of CD86 was most pronounced with addition of the 
calcium ionophore ionomycin. However, the output number of viable cells after 
differentiation was decreased by PMA plus TNF-a (P > 0.05) or ionomycin (P < 0.05) 
compared with that in PMA alone (Figure 23). This observation is in accordance with the 
finding that the percentage of apoptotic cells of stimulated KG1 myeloid cell line with PMA 
plus TNF-a or ionomycin was increased compared with that stimulated with PMA alone    
(St. Louis et al., 1999).  
 
 
3.3.2.5  PMA-generated DC from CD34+ progenitors are functio al APCs 
 
The functional hallmark of DC is their ability to activate T cells (Caux et al., 1990; 
Rosenzwajg et al., 1996; Zhou and Tedder, 1996). While T cell proliferation was induced by 
autologous PMA-generated DC in the presence of SEB or TT, PMA-generated DC can’t 
induce the proliferation of autologous T cells in the absence of Ag (Figure 24). This lack of 
proliferation, in the absence of Ag, makes it unlikely that T cell proliferation is due to phorbol 
ester carryover. In addition, SEB and TT did not induce T cell activation in the absence of 
PMA-derived DC. SEB-mediated T cell activation is not MHC restricted and does not require 
antigen (Ag) processing but TT-mediated T cell proliferation is MHC restricted and require 
both Ag processing and presentation. As presented in Figure 24, only minimal proliferation 
can be demonstrated for T cells with added autologous monocytes in the presence of SEB or 
TT. In contrast, after adding autologous CD34+-derived DC, a marked proliferation could be 
induced.  
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Figure 23: Viable cell counts of PB-derived dendritic cells after one week stimulation with 
serum-free medium (CellGroÒ DC) containing PMA alone or plus TNF-a or ionomycin.  
* Significant, P < 0.05, Kruskal-Wal is test  
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Figure 24: Autologous T cell proliferation induced by PMA-generated DC, from PB-CD34+ 
cells, pulsed with staphylococcal enterotoxin B (SEB) or preservative-free tet nus toxoid 
(TT). Monocytes or day 7 g-irradiated DC (2 ´  104 cells) were added to purified autologous   
T cells (1 ´ 105 cells) in the absence or presence of 3 mg/ml SEB or 10 mg/ml TT. As negative 
controls, autologous T cells were plated in triplicate wells of 96- l  flat-bottom plates with 
media alone (no stimulus) or with media containing SEB or TT. Data are presented as the 
mean CPM ± SD of triplicate cultures.  
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3.4  Retroviral transduction 
 
3.4.1  High titer virus production 
 
The efficacy of GP+E86 ecotropic producer cell line to produce high-titer murne elper-f ee 
retroviruses (that are capable of delivering genes to dividing murine cells) appears to be 
limited by the low transfectability of these packaging cells. Figure 25 shows that the 
percentage of transfected cells expressing EGFP not exceeded 3 % aft r transfection with 
pSFbEGFP retroviral vector using electroporation or SuperFectTM Transfection Reagent.  
 
     Mock-transfected cells                                 pSFbEGFP-transfected cells  
                                                     Electroporation                   SuperFectTM R agent 
                                               
                                                                         
Figure 25: Flow cytometric analysis of ecotropic GP+E86 packaging cells transfected with 
pSFbEGFP retroviral vector containing EGFP via electroporation or SuperFectTM 
Transfection Reagent. Mock (no retroviral vector-DNA) transfected cells were used as 
negative control.  
 
Recently, the laboratory of Nolan (Dr. Garry P. Nolan, Department of Molecular 
Pharmacology, Standford University School of Medicine) created a new producer cell line 
[Phoenix Eco (FNX-Eco) and Phoenix Ampho (FNX-Ampho)] derived from the highly 
transfectable 293T cell line to generate high-tit r helper-free retroviruses by transient 
transfection (Pear et al., 1993; Yang et al., 1999). The new producer cell line Phoenix was 
highly transfectable with SuperFect reagent than calcium phosphate precipitation method  
(Figure 26). The highest transfection efficiency (74.4 %) and a virus titer (4 ´ 106 CFU/ml) 
was obtained with the cells that were 2 ´ 106 at seeding, 24 h before transfection, using 
SuperFect reagent (Figure 27). 
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 Calcium phosphate precipitation method                          SuperFectTM Reagent                    
          
 
Figure 26: Fluorescence microscopic image of transient transfected Phoenix cells with 
pSFbEGFP retroviral vector via calcium phosphate precipitation method or SuperFectTM 
Transfection Reagent. 
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Figure 27: Transient transfection efficiency as measured by EGFP expression and virus titer 
production of Phoenix cells transfected at different confluent percentages with pSFbEGFP 
retroviral vector via SuperFectTM Transfection Reagent. Different cell numbers                 
(0.1-2.5 ´  106) were seeded in 100-mm tissue culture dishes t  day before transfection. 
Transfections were occurred with 10 mg retroviral vector/60 ml SuperFect reagent. The 
complex incubation time on cells was 2.5 h. Analysis was performed 48 h post-transfection. 
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In this study, transient transfection of human ecotropic pa kaging cells, FNX-Eco using a 
SuperFect reagent was utilized to produce high-titer murine recombinant retroviral vectors   
(> 1 ´ 106 CFU/ml) that used for transduction of murine pseudotyped packaging cells PG13 
to generate high-titer (> 5 ´ 105 CFU/ml) retroviruses pseudotyped with gibbon ape leukemia 
env protein (to increase the transduction efficiency to dividing human progenitor cells). The 
pseudotype retrovirus-containing supernatants were harvested under serum-f ee conditions 
(CellGroÒ SCGM), to avoid skewing the resulting immune response by foreign antigens 
present in FCS, at 37°C as described previously (Glimm et al., 1998) because PG13 rapidly 
looses viral titer when grown at the lower temperature (Re ves et al., 2000).   
 
 
3.4.2  CD34+ progenitor cells transduction 
 
The expansion of primitive progenitor cells in culture should facilitate retroviral transduction 
because retroviral vectors require target cell division for efficient integration into cellular 
genome (Glimm et al., 1998). The data in Table 3 and Figure 15 indicated that CD34+ 
progenitor cells were expanded highly in CellGroÒ SCGM containing Flt-3L, 300 ng/ml;    
IL-3, 100 ng/ml and SCF, 100 ng/ml. Here, different methods were used for retr viral 
transduction of CD34+ haematopoietic progenitor cells in serum-f ee medium to determine the 
optimal transduction conditions. The best result were obtained with the following conditions: 
CD34+ progenitor cells (5 ´ 104) were stimulated firstly for 48 h with the above cytokine 
cocktail in complete serum-f ee medium CellGroÒ SCGM. Subsequently, cells were infected 
with 1 ml pseudotyped viral supernatants (> 5 ´ 105 CFU/ml, made in serum-free medium) in 
the presence of protamine sulphate (5 mg/ml) and cytokines with centrifugation at 1000 x g 
for 2 h at room temperature. Cells were then incubated at 37°C in 5 % CO2. On the next day, 
supernatants were removed and cells were cultured in fresh medium supplemented with 
cytokines. Three rounds of consecutive transductions were performed on days 3, 5 and 7, 
respectively. The efficiency of the transduction was monitored one week after the last 
infection. Figure 28 exhibits the surface antigen phenotype characterization f CD34+ 
progenitor cells after expansion and transduction under the above conditions. The cells were 
negative for CD1a, CD15 and CD14. In addition, only 3.9 % ± 0.3 % (n = 3) were CD86+. On 
the other hand, the level of CD34 expression was 78.9 % ± 4.7 % (n = 3). Cell viability during 
expansion and transduction under serum-f e  conditions was greater than 90 %. 
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Figure 28: Surface Ag phenotype chara terization of CD34+ progenitor cells after expansion 
and transduction in serum-f ee medium CellGroÒ SCGM containing Flt-3L (300 ng/ml), IL-3 
(100 ng/ml) and SCF (100 ng/ml). Isotype-match d controls are indicated by dotted lines.  
1Mean ± SD of three different experiments 
 
Cell surface FLAG expression of pSFbS(FLAG-VLIgPl)wDAF-transduced CD34
+ progenitor 
cells was 45.9 % ± 4.0 % (n = 3) one week after the last infection (Figure 29). FLAG signals 
from pSFbS(FLAG-VLIgPl)wDAF-transduced CD34
+ progenitor cells could be released by  
PI-PLC indicating that the retroviral vector targets the fusion protein to the cell surface via 
GPI-anchor (Figure 29). 
 
 
 
Figure 29: FLAG expression and PI-PLC release of pSFbS(FLAG-VLIgPl)wDAF-transduced 
CD34+ progenitor cells. Thin and thick lines indicate transduced cells treated with or without 
PI-PLC, respectively. Dotted line represents the mock-transdu ed cells. M2: Anti-FLAG 
antibody-binding.  
1Mean ± SD of three different experiments 
 45.9% ± 4.0%1 
78.9% ± 4.7%1 3.9% ± 0.3% 
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3.4.3  VLIgPl gene expression in dendritic cells 
 
Figure 30 shows typical morphology of cytokine- and PMA-derived DC obtained from 
transduced CD34+ progenitor cells under-serum free conditions. Cell aggregates and 
numerous cytoplasmic protrusions (veils) are a characteristi featur  of cytokine- and PMA-
derived DC, morphology reported to be characteristic of mature DC (Hart, 1997). These veils 
usually extend from all parts of the cells. Occasionally, cells were observed with polarized 
veils (Thurnher et al., 1997). In addition, a subset of PMA-derived DC developed long 
dendrites. 
 
                     Cytokine-derived DC                                       PMA-derived DC 
    
       
 
Figure 30: Morphology of the cytokine- a d PMA-derived DC obtained from pSFbS(FLAG-
VLIgPl)wDAF-transduced CD34
+ cells under serum-free conditions. Arrows indicate hair-like 
cytoplasmic projections and elongated dendrite.
 
Table 5 shows that all PMA-derived DC were negative for CD1a and positive for CD40, 
CD83, CD86 and MHC-class I and II. On the other hand, in cytokine-derived DC only      
52.2 % ± 5.3 %, 41.8 % ± 3.1 %, 26.3 % ± 2.4 % and 14.4 % ± 5.2 % (n = 3) were CD86+, 
CD1a+, CD83+ and CD40+, respectively.  
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Surface antigen Cytokine-derived DC PMA-derived DC 
CD1a (41.8 % ± 3.1 %1, ++) - 
CD40 (14.4 % ± 5.2 %, +) + 
CD83 (26.3 % ± 2.4 %, +) ++ 
CD86 (52.2 % ± 5.3 %, ++) +++ 
MHC class I ++++ ++++ 
MHC class II ++++ ++++ 
  
Table 5: Surface Ag phenotype characterization of cytokine- and PMA-derived DC obtained 
from transduced CD34+ cells cultured in serum-free medium CellGroÒ DC for indicated 
periods of time as mentioned in material and methods. Each + indicates an increase of         
0.5 logs in mean fluorescent intensity versus isotype matched control nd - and ( ) indicate all 
cells are negative or subpopulation only is positive, respectively. 
1Mean ± SD of three different experiments 
 
In addition, co-expression of VLIgPl gene and CD86, the most important ligand to induce 
CD28-mediated co-stimulation for CD8+ T cell activation, i creased in PMA-derived DC 
compared with cytokine-derived DC; 53.8 % ± 2.8 % (n = 3) versus 32.1 % ± 2.1 % (n = 3), 
respectively (Figure 31). These data indicated that PMA-derived DC are more homogeneous 
and mature than cytokine-derived DC. 
 
              Cytokine-derived DC                                   PMA-derived DC 
               
 
Figure 31: Co-expression of VLIgPl gene and CD86 of the cytokine- and PMA-derived DC 
obtained from pSFb ( LAG-VLIgPl)wDAF-transduced CD34+ cells under serum-free 
conditions. M2: Anti-FLAG antibody-binding. 
1Mean ± SD of three different experiments 
 
32.1% ± 2.1%1 53.8% ± 2.8% 
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3.5  An in vitro autologous T cell response against VLIgPl 
 
3.5.1  VLIgPl-expressing dendritic cells induce an in vitro autologous T cell proliferation 
 
Figure 32 demonstrates the successful activation and proliferation of autologous T cells by 
pSFbS(FLAG-VLIgPl)wDAF-transduced DC. This proliferative response is more prominent in 
PMA-derived DC (PI = 328.54) compared to cytokine-derived DC (PI = 143.29) indicating 
that PMA-derived DC are more potent in activating autologous T cell proliferation. The 
proliferative response could be augmented by increase of the percentage of pSFbS(FLAG-
VLIgPl)wDAF-transduced DC (Figure 33). 
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Figure 32: Autologous T cell proliferative response induced by cytokine-derived DC 
compared with PMA-derived DC obtained from transduced CD34+ cells. Mock-transduced 
DC were used as negative control. In addition, transduced DC or autologous T cells were 
plated in triplicate wells of 96-well flat-bottom plates with media alone.Data are presented 
as the mean CPM ± SD of triplicate cultures. Proliferative index (PI) value is the ratio 
between the mean CPM of T cells in the presence and in the absence of transduced DC in the 
cultures. DC/Mock, mock-transduced DC; DC/FLAG, pSFbS( LAG)wDAF-transduced DC; 
DC/EGFP, pSFbEGFP-transduced DC; DC/NeoR, pSFb1N-transduced DC; DC/FLAG-VLIg, 
pSFbS(FLAG-VLIgPl)wDAF-transduced DC. 
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Figure 33: Autologous T cell proliferative response induced by different concentration of 
PMA-derived DC obtained from pSFbS(FLAG-VLIgPl)wDAF-transduced CD34+ cells. Data 
are presented as the mean CPM ± SD of triplicate cultures. Proliferative index (PI) value is 
the ratio between the mean CPM of T cells in the presence and in the absence of transduced 
DC in the cultures. 
 
The absence of autologous T cell proliferation in the presence of mock- or 
pSFbS(FLAG)wDAF-transduced DC indicates that the proliferation induced by pSFbS(FLAG-
VLIgPl)wDAF-transduced DC is specific for VLIg of plasmocytoma (Figure 32). On the other 
hand, moderate proliferation in the presence of autologous DC transduced with pSFbN1 
(containing NeoR) or pSFbEGFP (containing EGFP) has been observed (Figure 32). This data 
supports the idea that neomycin and EGFP by themselves are immunogenic.  
 
 
3.5.2  MHC-restriction of T cell response 
 
To determine MHC restriction of the VLIgPl-induced proliferation, the inhibitory effect of 
anti-HLA antibodies on their autologous T cell proliferation was studied. Figure 34 
demonstrates that autologous T cell proliferation was almost completely inhibited by 
monoclonal antibody against MHC class I (HLA-ABC). There was only minor inhibition by 
antibodies against MHC class II (HLA-DR). In addition, no significant inhibition was found 
with control mouse mAbs. These data indicated that the elicited proliferative response is not 
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directed against the constructed whole GPI-linked fusion protein present at the surface of 
transduced DC. Proliferation is rather stimulated by fragments of the transduced peptide 
presented on MHC class I molecules. 
 
An
ti 
- C
D8
6
An
ti 
- M
HC
 c
la
ss
 I
An
ti 
- M
HC
 c
la
ss
 II
Co
nt
ro
l I
gG
0
25
50
75
100
%
 I
n
h
ib
it
io
n
 
 
Figure 34: Inhibition (%) of autologous T cell proliferation, induced by pSFbS(FLAG-
VLIgPl)wDAF-transduced DC, by antibodies against MHC class I (HLA-ABC), class II    
(HLA-DR), CD86 (B7-2) or an isotypic control mouse IgG. Data are presented as the mean 
CPM ± SD of triplicate cultures.  
 
 
3.5.3  Inhibitory effect of CD86 antibodies on T cell response 
 
The expression of co-stimulatory molecules on APC plays a major role in the activation of    
T cells. Therefore, the inhibitory effect of CD86 antibodies on autologous T cell proliferation 
induced by VLIgPl-transduced DC was examined. As shown in Figure 34, autologous T cell 
proliferation was almost completely blocked by CD86 antibodies indicating the critical role of 
this co-stimulatory molecule in activation of naive T cells. 
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4   Discussion 
 
 
Multiple myeloma (MM) is a malignant disease commonly affecting elderly individuals and 
characterized by accumulation of mature plasma cells in the bone marrow. Although it is 
possible to induce transient remission of disease by chemotherapy, the disease is essentially 
incurable. Therefore, novel approaches are much needed (Lim and Bailey-Wood, 1999; Wen 
et al., 2001). 
 
The pathophysiology of paraproteinemia could be elucidated by an increasing knowledge on 
normal B cell development. Early in normal B cell development the variable (V), diversity 
(D) and joining (J) segments of the immunoglobulin (Ig) heavy and light chain genes are 
rearranged to produce a functional V(D)J sequence coding for the antibody-combining site of 
the Ig molecule. This sequence is the same in all cells belonging to a particular B cell clone 
and can be used as a marker of the clone (Ludwig et al., 1999; Samson, 2000). The 
recombinations take place within the bone marrow without antigenic stimulation. Virgin        
B cells migrate then to the lymph nodes. In the primary antibody response, they give rise to 
lymphoblasts that in turn differentiate into short-lived plasma cells secreting IgM. In 
secondary antibody response the lymphoblasts migrate into germinal centers of the lymph 
nodes and, as a result of exposure to antigen, mutations take place in V(D)J sequence which 
improve antigen affinity (somatic hypermutation). During germinal center reaction, B cells 
with high affinity to antigens presented by follicular dendritic cells escape apoptosis to give 
rise to memory B cells, which can produce IgM secreting lymphoplasmacytoid cells or can 
undergo isotype class switching (Ig heavy chain constant region exchange) to produce cells 
secreting antibodies of different isotypes (IgG, IgA, IgE or ID). These cells do not proliferate 
within lymph nodes but home to bone marrow and develop there into long-liv d plasma cells. 
Isotype switching does not affect antibody specificity, but alters effector functions that an 
antibody can engage (Ludwig et al., 1999; Samson, 2000).  
 
The malignant clone for MM is derived from a cell, somatically hypermutated. The V genes 
show no clonal diversity and the V sequence remains stable during the course of disease. 
Thus, it is generally believed that the initial neoplastic event in MM occurs in a single post 
germinal-center B cell because at this stage in B cell development somatic hypermutation has 
ceased (Ludwig et al., 1999). Therefore, the idiotypic protein (Id) secreted by neoplastic 
 84
plasma cells represents an ideal tumor-specific antigen for immune targeting (Sahota et al., 
1997; Kosmas et al., 1999). This antigen is supposed to exhibit a low immunogenicity (Lim 
and Bailey-Wood, 1999). Most studies addressing the capacity to elicit an anti-idiotypic 
immune response have analyzed the target antigen as a paraprotein taken up by DC (Lim and 
Bailey-Wood, 1999; Reichardt et al., 1999; Hajek and Butch, 2000; Timmerman and Levy, 
2000; Titzer et al., 2000) and presented on almost MHC class II molecules. However, the 
response in vivo seems to be modest and transient (Wen et al., 2001). Idiotypic gene transfer 
into dendritic cells represents an alternative for induction of an anti-idi typic immune 
response. Because internally produced peptides are presented differently (on almost MHC 
class I molecules), this procedure may elicit a more efficient cytotoxic immune response. 
 
Due to genetic recombination, in several myelomas neoplastic c lls don’t produce 
immunogloblin heavy chain leading to the appearance of free monoclonal light chains (Sakai 
et al., 1993). Therefore, in most cases of plasmocytoma, the variable region of the 
corresponding light chain (VLIgPl) can be used as a defined tumor-ass ciated antigen. This 
thesis provides evidence that a considerable syngeneic T cell proliferation restricted to MHC 
class I molecules can be elicited in vitroagainst VLIgPl through autologous dendritic cells via 
a retroviral transduction of human CD34+ progenitor cells under serum-free conditions. The 
VLIgPl gene used by the tumor cells in this study was a V segment of the VkIV subgroup. 
 
 
4.1  A novel retroviral expression-cl ing vector 
 
Retroviral vectors are able to introduce new genes with stable expression and at high 
efficiency into the genome of many types of mammalian cells, including primitive 
haematopoietic cells (Miller, 1992).  
 
The objective of this work was to induce efficient transfer and expression of VLIgPl gene in 
DC. Therefore, the SFFVp/MESV hybrid retroviral vector backbone has been chosen, 
designed to overcome transcriptional inefficiency and silencing associated with retroviral 
gene transfer into myeloid progenitors and haematopoietic stem cells (Baum et al., 1995). 
Due to the mechanism of reverse transcription, the integrated provirus contains the leader 
sequence of the murine embryonic stem cell virus (MESV) and a modified LTR of the spleen 
focus-forming virus (SFFVp) in its 5'end. This LTR has been re- gineered to avoid 
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recombination of the provirus and minimize the risk of producing helper viruses. The          
U3 region of SFFVp showed higher enhancer activity than that of Moloney murine leukemia 
virus (M-MLV). The presence of both retroviral cis e ements allows efficient and long-term 
gene expression in the myeloid compartment (Bau  t al., 1995). 
 
The Adoption of marker genes that can be rapidly monitored and used for efficient selection 
of transduced cells will facilitate the improvement of gene marking protocols. To date the 
neomycin phosphotransferase (Neo) gene has been the most widely used marker in clinical 
studies (Rill et al., 1992; Brenner et al., 1993; Dunbar et al., 1995; Cornetta et al., 1996; 
Heslop et al., 1996). However, the introduction of Neo is hampered by non-specific toxicity 
of neomycin and by potential immunoclearence of transduced cells (Brenner, 1996). 
Furthermore, selection is time-consuming. Cytochemical markers, such as b-g lactosidase 
(Strair et al., 1990; Bagnis et al., 1995), also have important limitations (Giaretta et al., 2000). 
In fact, The presence of endogenous activity in some cell types, the need to use fluorogenic 
substrates and the potential for passive transfer of the enzymatic activity to untransduced 
neighboring cells make this marker quite unreliable (Giaretta et al., 2000). Therefore, in this 
study, a novel retroviral expression-cloning vector that directs the tumor-associated antigen of 
plasmocytoma marked with a FLAG antibody-binding site to the plasma membrane via a 
glycosylphosphatidylinositol (GPI)-anchor has been constructed. The FLAG epitope consists 
of eight-amino acid peptide (DYKDDDDK) recognized by the commercially available 
monoclonal antibodies (M1, M2 and M5), raised against this peptide (Knappik and Pluckthun, 
1994). Using FLAG expression at the cell surface transduced cells can be immunoselected. It 
is not likely to obscure other epitopes, domains, or alter function, secretion, or transport of the 
fusion protein because of the small size of the FLAG peptide tag. The three anti-FLAG 
monoclonal antibodies (M1, M2 and M5) differ in their binding abilit es based on the location 
of the FLAG sequence in the fusion protein. The M1 antibody requires the FLAG to be at the 
very N-terminus of the fusion protein for high affinity binding and recognizes the sequence as 
small as DYKD or DYKDE (Knappik and Pluckthun, 1994). The M5 antibody binds with 
high affinity if the FLAG sequence is at the very N-terminus of the fusion protein and 
preceded by a methionine. Antibody M2 is the most versatile in its applications because it 
recognizes a FLAG-tagged fusion protein independently of the intramolecular location of the 
tag. M1 requires calcium ions for binding, whereas M2 and M5 are not calcium-dependent 
(Brizzard et al., 1994). 
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The GPI-anchored construct has been chosen because of its stable transgene surface 
expression without a major dependence on transcription rate. Low transcription rate might be 
a limiting factor of classical membrane proteins or fusion proteins such as nerve growth factor 
receptor [NGFR] or epidermal growth factor [EGF] (Austin et al., 2000). For targeting the 
transgene to a GPI-linked protein, the GPI anchoring determining sequences within decay-
accelerating factor (DAF) normally expressed in dendritic cells themselves have been used 
thus avoiding additional unphysiological peptides expressed in DC. DAF is a GPI-linked 
membrane glycoprotein that regulates complement by binding activated complement 
fragments, C3b and C4b, thereby inhibiting amplification of the complement cascade on host 
cell membranes (Nicholson-Weller et al., 1982; Medof et al., 1984; Kinoshita et al., 1986). 
The GPI-anchor consists of an ethanolamine phosphate, three mannose residues and a 
nonacetylated glucosamine linked to phosphatidylinositol (Masterson et al., 1989; Schubert   
et al., 1994; Udenfriend and Kodukula, 1995; Kinoshita and Inoue, 2000). GPI-anchor 
preassembly and addition to the protein apparently takes place in the endoplasmic reticulum 
(Bangs et al., 1985, 1986; Ferguson et al., 1986; Schubert et al., 1993; Udenfriend and 
Kodukula, 1995; Kinoshita and Inoue, 2000). Thereafter, the protein is transported to the cell 
surface via the Golgi apparatus (Caras, 1991). Two elements are required for anchor ddition, 
COOH-terminal hydrophobic domain (presumably removed during anchor attachment) and a 
second element, the cleavage/attachment site, located 10-12 residues NH2-terminal to the 
signal (Caras et al., 1989; Udenfriend and Kodukula, 1995). In addition, lacking of NH2-
terminal signal peptide of DAF (resides –34 to –1), that is necessary for translocation across 
the membrane of the endoplasmic reticulum, failed to produce GPI-anchor d protein 
suggesting that membrane translocation is necessary for anchor addition (Caras, 1991). 
Therefore, nascent proteins destined to be processed to a GPI-anchor re supposed to contain 
two hydrophobic signal peptides, one at NH2 terminus and another at the COOH terminus 
(Udenfriend and Kodukula, 1995; Tiede et al., 1999). Both are cleaved sequentially. After 
action of the NH2-terminal signal peptidase, the transamidase reaction will yield the mature 
GPI-linked protein (Amthauer et al., 1993; Udenfriend and Kodukula, 1995; Ramalingam et
al., 1996; Hiroi et al., 2000). The transamidation reaction involves formation of an activated 
carbonyl intermediate (enzyme-substrate complex) with the ethanolamine moiety of the 
preassembed GPI unit serving as a nucleophil (Maxwe l et al., 1995; Ramalingam et al., 
1996; Ohishi et al., 2001). To address these requirements, a fusion protein containing FLAG-
VLIgPl in frame between the two ends of DAF has been constructed. The first 34 and the last 
37 amino acids of DAF are hydrophobic domains cleaved upon attachment to the GPI-a chor 
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molecule (Moran et al., 1991). In addition, the cleavage attachment site (w) is located within 
the carboxyterminus leading to GPI-linked transgene expression provided by this vector. 
 
The pSFbS(FLAG-VLIgPl)wDAF retroviral vector successfully targeted the FLAG-VLIgPl 
fusion protein to the cell surface of transfected Jurkat wild type cells via electroporation. The 
percentage of FLAG expression in transfected Jurkat cells increased by increasing cell 
number, amount of DNA, voltage and capacity and decreasing the final volume at 
electroporation. FLAG signals from transfected cells could be released by PI-PLC indicating 
that the retroviral vector targets the fusion protein to the cell surface via GPI-anchor. Xba1 
and Cla1 restriction sites are not present in any type of human V genes. Thus, any type of the 
VLIg can be directly cloned into this expression vector via Xba1 and Cla1 restriction sites. As 
a result, the vector pSFbS(FLAG)wDAF without the VLIgPl directs the FLAG to the plasma 
membrane and can be used as a control for immune response. 
 
 
4.2  PMA-derived DC under serum-free conditions 
 
DC are attractive cellular adjuvants for vaccination strategies due to their professi nal 
antigen-presenting capacity (Brossart et al., 2000; Klein et al., 2000). Currently, most in vitro 
culture systems for the production of these DC include serum. However, this is undesirable 
because serum contains growth factors that vary between individuals and could affect DC 
development (Luft et al., 1998). Unless the individual’s own serum is used, serum adjuvants 
such as FCS will lead to a skewing of the immune response by foreign antigens. In addition, 
serum preparations contain a series of cytokines not yet identified which are possibly involved 
in DC differentiation. In order to study the requirements to differentiate a CD34+ cell into DC, 
this study provides data that DC can differentiate out of CD34+ cells from different origins in 
the presence of PMA without addition of serum. Here, CD34-derived dendritic cells (CD34-
DC) were chosen because their preferential capacity to activate CD8+ T cells compared to 
monocyte-derived DC (Ferlazzo et al., 1999). In addition, murine oncoretroviral vectors 
require cell division for integration into the nucleus (Glimm et al., 1998). Differentiation of 
monocytes to DC does not involve any cell division (Kiertscher and Roth, 1996; Zhou and 
Tedder, 1996; Ardeshna et l., 2000b). This is only provided by CD34+ cells stimulated with 
cytokines before differentiation to DC. 
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Human mature DC with typical morphology (large and loosely adherent, and a subset 
developed long dendrites and h ir-like cytoplasmic projections) and surface antigen 
phenotype (CD1a-, CD83+ and CD86+) were obtained from CB- and PB-CD34+ progenitor 
cells after one week of culture in serum-free medium upon stimulation with PMA alone. In 
addition, these cells were CD1a- throughout all experiments indicating that PMA induces DC 
differentiation without causing the generation of cellular intermediates. Morphological 
changes began within one day of stimulation, were fully manifested within three days, and 
were stable over at least 2 weeks in culture. The same result was obtained from ex vivo 
expanded BM-CD34+ cells.  
 
As described previously, there are two stages of DC differentiation from CD34+ 
haematopoietic progenitor cells (HPC) using cytokines (Winzler t al., 1997). The first stage 
involves proliferation and differentiation of HPC to immature CD1a+DC, cells exhibiting a 
high capacity for Ag uptake but relatively poor ability to activate T cells. This intermediate 
DC adhered to plastic surfaces, express d Birbeck granules, and were negative for CD80, 
CD83 and CD86 co-stimulatory molecules. This differentiation is induced in vitro within       
2 weeks by GM-CSF, TNF-a and other cytokines (Luft et al., 1998). The second stage 
involves maturation of immature CD1a+ C to mature DC, cells that have decreased Ag 
uptake capability but are much more potent in activating T cells. This maturation involved 
increased expression of CD80, CD83, CD86, HLA-A, -B, -C, and -DR as well as down-
regulation of CD1a and CD11b. Activated DC are characterized by the lack of adherence to 
plastic surfaces and the absence of Birbeck granules (Luft et al., 1998). In vitro 
maturation/activation can be induced by TNF-a ± other cytokines (Hart, 1997) or CD40 
receptor cross-linking (Flores-Romo et al., 1997). Spontaneous maturation of intermediates 
into fully active DC expressing CD83 and co-stimulatory molecules occurred asynchronously 
over the ensuing 2-3 weeks. In vivo this second stage is triggered by bacteria or its 
components (LPS and DNA), viral infection and inflammatory cytokines (Banchereau et al., 
2000).  
 
Because cytokine receptor stimulation activates complex signalling cascades that initiate 
multiple responses, differentiation to other lineages is almost simultaneously induced. Thus 
cytokine application not only generates DC but also macrophages and neutrophils as well 
(Santiago-Schwarz et al., 1992; Szabolcs et al., 1995; Bender t al., 1996). In contrast to 
cytokines or CD40 ligand, PMA alone induces DC differentiation, without causing cell 
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proliferation and the generation of cellular intermediates (Davis et al., 1998). In this regard, 
PMA-induced DC differentiation from CD34+ cells more closely resembles cytokine-drive  
DC differentiation from monocytes. There is also no proliferation, and 20-90 % of input cells 
are lost during culture (Ki rtscher and Roth, 1996; Zhou and Tedder, 1996; Ardeshna et al., 
2000b). The observation that about 40-60 % of cells are lost during culture depending upon 
the source of CD34+ progenitors is supported by the observation that PMA had a negative 
effect on CD34+ cell survival that did not differentiate to DC (Davis et al., 1998). The ability 
to differentiate into DC in response to PMA is limited to CD34+ cells, as PMA caused 
macrophage differentiation in CD34-CD15+ cells and cell death in CD14+ monocytes (Davis 
et al., 1998). In addition, CD34+ myeloid cell line KG1 differentiates into dendritic-like cells 
in response to PMA (with or without the calcium ionophore ionomycin or TNF-a). 
Comparison of KG1 to the PMA-unresponsive subline KG1a reveals differences in 
expression of TNF receptors (1 and 2), PKC isoforms (a, b1, b2 and m) and RelB, suggesting 
that these components/pathways are important for DC differentiation (St. Louis et al., 1999). 
All receptor-mediated stimuli (GM-CSF, IL-4, TNF-a and CD40 cross-linking) that induce 
DC differentiation can also activate PKC as part of their intracellular signalling pathways 
(Arruda and Ho, 1992; Ren et al., 1994; Mufson, 1997). Direct activation of PKC with PMA 
alone is sufficient to induce differentiation of human BM-CD34+ cells into mature and fully 
functional DC within 7 days only, suggesting a critical and specific role of this pathway for 
the progenitor lineage committed to DC (Davis et al., 1998). This specificity may facilitate 
further identification of signalling pathways involved in DC differentiation.  
 
The rarity of CD34+ HPC makes sufficient isolation for larger scale studies difficult. This 
problem could be overcome by x vivo CD34+ cell expansion. The effects of different 
cytokine combinations and culture conditions on BM-CD34+ cell expansion were examined 
(Table 3). According to these data, the best conditions for expansion of CD34+ cells are 
provided in serum-free medium (CellGroÒ SCGM) containing Flt-3L, IL-3 and SCF. In the 
case that 50 % of the cytokine-containing medium was exchanged after 3 days and the density 
of cells did not exceed 105 cells/ml, the increase of cells was 18.5-fold. The DC 
differentiation induced by PMA was not affected by pretreatment of the BM-CD34+ cels with 
the above cytokine cocktail that induced CD34+ cell expansion connected with myeloid but 
not with DC differentiation (Davis et al., 1998). The expansion of primitive progenitor cells 
in culture should facilitate retroviral transduction because retroviral vectors require target cell 
division for efficient integration into cellular genome (Glimm et al., 1998). Therefore, the 
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method described here may be used preferentially for introducing genes into DC by 
oncoretroviral vectors under serum-free conditions.  
 
To study the efficacy of PMA to generate mature DC in serum-free medium, PMA-derived 
DC compared with cytokine-derived DC were cultured using the same serum-free c lture 
conditions. The maturation of cultured human blood DC was delineated by surface analysis of 
the co-stimulatory molecule B7-2 (CD86), because it is the most important ligand to induce 
CD28-mediated co-stimulation for CD8+ T cell activation (Van Gool et al., 1999). It is well 
known that the cytokine requirements to differentiate CB- and PB- D34+ progenitor cells into 
DC are different (Garbe et al., 1998). Therefore, CD34+ progenitors from CB and PB have 
been compared within the same experiment. CD86+ yield under serum-free conditions was 
increased by PMA compared to cytokine cocktails in CB (P = 0.071) and PB (P = 0.016). Up-
regulation of CD86 was most pronounced with addition of the calcium ionophore ionomycin. 
However, the output number of viable cells after differentiation was decreased by PMA plus 
ionomycin (P < 0.05) or plus TNF-a (P > 0.05) compared with that in PMA alone. The 
decrease of cell viability using PMA plus ionomycin or TNF-a compared to PMA alone may 
be due to apoptotic effect of these two stimuli. TNF-a and ionomycin appear to be using the 
same signalling pathway because the combination of PMA, ionomycin and TNF-a was o 
different from PMA plus TNF-a or ionomycin (St. Louis et al., 1999).  
  
Functionally, PMA-generated DC were capable of stimulating autologous T cell proliferation 
by processing and presenting whole soluble Ag or SuperAg. The absence of autologous T cell 
proliferation when cultured with DC (no SEB or TT) demonstrates that DC themselves or the 
drug by which they have been treated do not stimulate responding T lymphocytes.  
 
Taken together, it can be concluded that PMA is a potent activator for differentiation of 
human CD34+ cells into mature DC in serum-free medium. The procedure described here may 
represent a method for generating pure populations of DC from freshly isolated or ex vivo 
expanded CD34+ progenitor cells. This may facilitate an in vitro immune response using 
primed or genetically modified DC against infectious and tumor-associated antigens.  
 
 
 91
4.3  High titer virus production in serum-free medium 
 
The use of retroviral vectors for human gene therapy requires the production of large 
quantities of high titer vector stocks (McTaggart and Al-Rubeai, 2000). The efficacy of 
GP+E86 ecotropic producer cell line to produce high-t ter murine helper-fr e retroviruses 
(capable of delivering genes to murine cells) appears to be limited by the low transfectability 
of these packaging cells. The percentage of transfected cells expressing EGFP not exceeded   
3 % after transfection with pSFbEGFP retroviral vector using electroporation or SuperFectTM 
Transfection Reagent.  
 
The infectious titer generated by such packaging cells derived from NIH/3T3 cells is 
generally low, necessitating identification of those clones that produce retroviruses at higher 
titer. Under optimal circumstances, this requires 1-2 months and must be repeated for each 
different construct. During prolonged selection process, the retroviral vector mRNA may 
inhibit growth of the packaging line, favouring the outgrowth of clones that produce low 
levels of virus; thereby, making it difficult to identify clones continuously producing 
retrovirus at a high titer (P ar et al., 1993). As a result of these deficiencies, transient 
production of retroviral supernatants has become the preferred method of producing retrovirus 
for most laboratory uses (P ar et al., 1993). In comparison to the production of stable 
retroviral producer cell lines, generation of high-titer retrovirus by transient production not 
only is less laborious, but also has allowed the production of high-titer retroviral supernatants 
from cDNAs that can’t be produced by stable producer cell lines. Transient transfection has 
also increased the versatility of retrovi us-mediated gene transfer to include the rapid testing 
of different constructs, viral pseudotyping, and the construction of retroviral cDNA libraries 
(Pear et al., 1993). 
 
Recently, the laboratory of Nolan created a new producer cell lin  [Phoenix Eco (FNX-Eco) 
and Phoenix Ampho (FNX-Ampho)] derived from the highly transfectable 293T cell line to 
generate high-titer helper-free retroviruses by transient transfection (Pear et al., 1993; Yang et
al., 1999). The new producer cell line Phoenix was highly transfectable with SuperFect 
reagent than calcium phosphate precipitation method. The highest transfection efficiency 
(74.4 %) and a virus titer (4 ´ 106 CFU/ml) was obtained with the cells that were 2 ´ 106 at
seeding, 24 h before transfection, using SuperFect reagent. 
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The range of cells that are infectable is determined primarily by the envelope protein of the 
virus and the presence of appropriate receptors for this protein on the surface of infected cells 
(Miller et al., 1991). One restriction of retroviral gene transfer into ha ma poietic stem cells 
is the low level of amphotropic virus receptor (von Laer et al., 2000). The virions produced by 
the murine pseudotyped packaging cells PG13 are hybrids between the gag-pol proteins of 
Molony murine leukemia virus (M-MLV) and the nv protein of gibbon ape leukemia virus 
(GaLV). These hybrid GaLV pseudotype virions are able to infect cells from higher mammals 
and human better than amphotype virions (Miller et al., 1991).  
 
Retroviral vectors have proven useful in a variety of gene transfer applications. A key feature 
of their utility is the availability of retrovirus packaging cells that allow production of 
retroviral vectors in the absence of helper virus. The GaLV-based packaging cells (PG13) 
have been constructed on the basis of murine cells that don’t express the receptor for GaLV. 
Thus, infection of packaging cells and the potential for generation of recombinant vectors is 
supposed to be very low (Miller et al., 1988, 1991). 
 
In this study, transient transfection of human ecotropic pa kaging cells, FNX-Eco using a 
superFect reagent was utilized to produce high-titer murine recombinant retroviral vectors       
(> 1 ´ 106 CFU/ml) used for transduction of murine pseudotyped packaging cells PG13 to 
generate high-titer (> 5 ´ 105 CFU/ml) retroviruses pseudotyped with gibbon ape leukemia 
env protein (to increase the transduction efficiency to dividing human progenitor cells). The 
pseudotype retrovirus-containing supernatants were harvested under serum-f ee conditions 
(CellGroÒ SCGM), to avoid skewing the resulting immune response by foreign antigens 
present in FCS, at 37°C as described previously (Glimm et al., 1998). The temperature to 
produce viral particles was not decreased because PG13 rapidly looses viral titer when grown 
at the lower temperature (Reeves et al., 2000).   
 
 
4.4  VLIgPl gene expression in dendritic cells 
 
Gene transfer and expression of exogenous genetic information coding for an immunogenic 
protein in DC can promote an immune response (Chischportich et al., 1999). Mobilized 
CD34+ cells represent an optimal source for the generation of mature and unctional DC 
suitable for cancer immunotherapy (Ratta et al., 1998). Despite advantages of both retroviral 
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vectors and hematopoietic stem cells as tools for genetic therapy, retroviral gene transfer into 
primitive stem cells of large animals has been problematic (MacNeill et al., 1999). This is due 
to multiple different factors, including low level expression of amphotropic retroviral 
receptors, Go/ 1 cell cycle status of progenitors and possible induction of differentiation o  
primitive haematopoietic progenitors on the attempt to induce cell proliferation (Richardson 
and Bank, 1996; Chu et al., 1998; von Laer et al., 2000). These problems could be overcome 
by using the GaLV pseudotype virions with SFFVp/MESV hybrid retroviral vector backbone 
and the cytokine cocktail induced CD34+ cell expansion without DC differentiation. Other 
factors include low viral titer, short half-life of the retroviral vector and Brownian movement 
of the retrovirus (Andreadis et al., 1997; Palsson and Andreadis, 1997). To overcome these 
limitations, high titer retroviruses produced by transient transfection were used. However, 
increased viral titer does not always correlate with enhanced gene transfer efficiency due to 
elevated levels of inhibitors and metabolic toxins secreted by the packaging cells. Serum-free 
viral supernatant may reduce the level of inhibitors and inactivators (Liu et al., 2000). 
 
One of the factors required for successful retroviral transduction is contact between viral 
particles and target cells. Combining agents that improve virus-ta get cell interaction via 
different mechanisms will increase transduction efficiency (Liu et al., 2000). Polycations such 
as polybrene and protamine sulphate increase the infection efficacy of the retroviral vector by 
reduction of electrostatic repulsion between virus and target cells (Liu  al., 2000). 
Concentrations of 5-10 mg/ml of protamine sulphate provided essentially the same infection 
efficiency as polybrene with low toxicity on a range of cell types (Cornetta and Anderson, 
1989). Efficient retroviral gene transfer into haematopoietic stem and progenitor cells can also 
be achieved by co-localizing retrovirus and target cells on specific adhesion domains of 
recombinant fibronectin (FN) fragments (Hanenberg et al., 1997). 
 
Here, different methods were used for retr viral transduction of CD34+ haematopoietic 
progenitor cells in serum-free medium to determine the optimal transduction conditions. The 
best result was obtained i  presence of the polycation protamine sulphate combined with 
centrifugation at 1000 x g for 2 h at room temperature. Cell surface expression of FLAG by 
pSFbS(FLAG-VLIgPl)wDAF-transduced CD34
+ progenitor cells was 45.9 % ± 4.0 % one 
week after three rounds of consecutive transductions. It could be released by PI-PLC that 
specifically cleaves proteins bound to the membrane via GPI-anchor (Moran et al., 1991). 
Surface antigen phenotype characterization f CD34+ progenitor cells after expansion and 
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transduction under serum-free conditions revealed that the cells were negative for CD1a, 
CD15 and CD14. In addition, only 3.9 % ± 0.3 % were CD86+. On the other hand, the level of 
CD34 expression was 78.9 % ± 4.7 %. These data indicated that the used cytokine cocktail 
induced CD34+ cell expansion without DC differentiation. 
 
The ability of cytokine- and PMA-derived DC obtained from transduced-CD34+ progenitor 
cells under serum-free conditions to express VLIgPl and co-stimulatory molecules important 
to activate T cells was compared in this thesis. It was found that, in spite of all cytokine-
derived DC were positive for MHC class I and II, only subpopulation was CD1a+, CD40+, 
CD83+ and CD86+ (Table 5). On the other hand, the entire population of PMA-derived DC 
was negative for CD1a and positive for other co-stimulatory molecules. In addition, co-
expression of VLIgPl gene and CD86 co-stimulatory molecule increased in PMA-derived DC 
compared with cytokine-derived DC. These data pointed out that PMA-derived DC are more 
homogeneous and mature than cytokine-derived DC. 
  
 
4.5  An in vitro T cell response against VLIgPl 
 
The existence of separate processing pathways for presentation of exogenous and endogenous 
antigens provided a suitable model for understanding how MHC class II-restricted CD4+ 
helper T-cell responses are generated against extracellular antigens while MHC class I-
restricted CD8+ cytotoxic T-cell responses are directed against cytosolic antigens. Exogenous 
antigens are internalized by APC, degraded in vesicular intracellular compartments, and 
loaded on MHC class II molecules in a post-Golgi compartment. In contrast, peptides derived 
from cytosolic antigens by the action of proteasomes are transported into the endoplasmic 
reticulum lumen by an adenosine triphosphate-dependent transporter associated with antigen 
presentation (TAP). In the endoplasmic reticulum lumen, a chaperone-medi ted assembly 
generates a stable complex containing MHC class I heavy chain, b2-microglobulin, and an 
antigenic peptide. This complex traffics to the cell surface, where it can be recognized by 
CD8+ T cells. The strict dichotomy was challenged by several studies that have shown that 
peptides generated from exogenous proteins can gain access to the cytosol and therefore be 
presented on class I MHC molecules (Bros art and Bevan, 1997). 
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MHC/peptide complexes by themselves do not initiate immune responses. An immune 
response follows a two-signal pattern, one corresponding to the MHC/peptide complex  
(signal 1) and another to a series of co-stimulatory molecules (signal 2), in particular B7 
molecules (Tarte et al., 1999; Ribas et al., 2000). A high density of B7 molecules is needed to 
trigger a full T cell response (Tarte et al., 1999). Presentation of tumor antigen by malignant 
cells not expressing co-stimulatory molecules is considered to be a major cause of the failure 
of the host’  immune response against tumors (Brown et al., 1998). Since antigen presentation 
is the deciding element between response or tolerance, a key pl yer is the APC, which has the 
greatest concentration of MHC/peptide and co-stimulatory molecules. When an antigen is 
presented by non-APC cells (tumor cells), the antigen is presented without co-stimulation 
(first signal without second signal), therefore a different T lymphocyte function such as 
anergy results (Guinan et al., 1994; Schwartz, 1996). If the same antigen is presented by APC, 
both first and second signals are present, the immune system senses danger to that tigen and 
triggers a full T cell response (Ribas et al., 2000). 
 
In multiple myeloma CD28 expression was present on most CD4 cells but lower on CD8 cells 
especially from those patients who also showed evidence of expanded T cell clones immunity 
(Brown et al., 1998). In addition, B7-1 (CD80) and B7-2 (CD86) are generally absent or o ly 
marginally present on tumor cells (Brown et al., 1998; Tarte et al., 1999; Pope et al., 2000). 
These results are consistent with the concept that engagement of the T cell receptor by tumor 
antigen on B7-1 deficient malignant plasma cells would result in T cell anergy rather than 
productive immunity (Brown et al., 1998). An activated CD8+ T cell that finds its specific 
MHC/peptide complex on the surface of a target cell triggers the killing mechanism without 
requiring the presence of signal 2 (Ribas et al., 2000). Therefore, vaccination of multiple 
myeloma patients with an in vitro activated autologous CTL against the tumor-associated 
antigen is needed. 
 
In order to proof that transduced DC are functional by eliciting an immune response, T cell 
proliferation against VLIgPl has been tested. It was found that pSFbS(FLAG-VLIgPl)wDAF-
transduced DC successfully activated proliferation of autologous T cells. This proliferative 
response is more prominent in PMA-derived DC (PI = 328.54) compared to cytokine-derived 
DC (PI = 143.29) indicating that PMA-derived DC are more potent to activate autologous     
T cell proliferation. The absence of autologous T cell proliferation in the presence of mock- or 
pSFbS(FLAG)wDAF-transduced DC indicates that the proliferation induced by  
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pSFbS(FLAG-VLIgPl)wDAF-transduced DC is specific for VLIg of plasmocytoma. The 
proliferative response was augmented by increase of the percentage of pSFbS(FLAG-
VLIgPl)wDAF-transduced DC and predominantly inhibited by antibodies against MHC class I 
or CD86. These data indicate that the elicited proliferative response is not directed against the 
constructed whole GPI-linked fusion protein present at the surface of transduced DC. 
Proliferation is rather stimulated by fragments of the transduced peptide presented on MHC 
class I molecules. 
 
On the other hand, moderate proliferation in the presence of autologous DC transduced with 
pSFbN1 (containing NeoR) r pSFbEGFP (containing EGFP) has been observed. These data 
support the idea that neomycin and EGFP by themselves are immunogenic.  
 
In conclusion, the data suggest that autologous T cells recognize immune epitopes within 
multiple myeloma variable region of paraprotein light chain, which had been presented by DC 
on MHC class I molecules. In addition, CD86 co-stimulation plays a critical role in activation 
of naive T lymphocytes. Thus a system was developed in itro, allowing further studies in 
vivo to determine the MHC restriction pattern of different VLIg peptides in different        
HLA-type multiple myeloma patients. Such results could provide the basis of a putative  
VLIg-based immunotherapy in multiple myeloma.  
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5  List of abbreviations 
 
  
7AAD 7-amino-actinomycin D 
a.a Amino acids 
Ag Antigen 
APC Antigen-presenting cells 
ATCC American Type Culture Collection 
BM Bone marrow 
Bp Base pairs 
BSA Bovine serum albumin 
CB Cord blood 
CB-DC Cord blood- erived dendritic cells 
CD Cluster of differentiation 
CD34-DC CD34-derived dendritic cells 
CDRIII Third complementarity-determining region 
CFU/ml Colony forming units per ml 
CPM Count per minute 
CTL  Cytotoxic T lymphocytes 
D Diversity gene segment 
DAF Decay-accelerating factor 
DC Dendritic cells 
DEPC-water Diethyl pyrocarbonate treated-w t r 
DMEM Dulbecco´s modified Eagle´s medium 
DMSO Dimethyl sulphoxide 
DNA Deoxyribonucleic a id 
E. coli Escherichia coli 
EGF Epidermal growth factor 
EGFP Enhanced green fluorescent protein
Env Envelope 
EP Electrophoresis  
FCS Fetal calf serum 
FGFR3 Fibroblast growth factor receptor 3 
FITC Fluorescein isothiocyanate 
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FLAG An artificial antibody-binding site 
Flt-3L Flt-3 ligand 
GaLV Gibbon ape leukemia virus 
G-CSF Granulocyte Colony-Stimulating Factor 
GM-CSF Granulocyte-Macrophage Colony-Stimulating Factor 
GPI Glycosylphosphatidylinositol 
H Hour 
HBSS Hank’s buffer saline solution 
HHV-8 Human herpesvirus-8 
HLA Human leukocyte antigens 
HPC Haematopoietic progenitor cells 
Id Idiotypic protein 
Ig Immuoglobulin 
IgH Immuoglobulin heavy chain 
IL Interleukin 
IMDM Iscove´s modified Dulbecco´s medium 
IPTG Isopropyl-b-D-thiogalactoside 
J  Joining gene segment 
Kb Kilo base pairs 
KSHV Kaposi's sarcoma-associated herpesvirus 
LB Luria-Bertani 
LTR's Long terminal repeats 
M  Monoclonal immunoglobulin 
M1, M2 and M5 Anti-FLAG monoclonal antibodies 
Mabs Monoclonal antibodies 
MACS Magnetic cell separator 
MESV Murine embryonic stem cell virus 
MGUS Monoclonal gammopathy of undetermined significance 
MHC Major histocompatibility complex 
MHH Hannover medical school 
Min Minute 
MLRs Mixed lymphocyte reactions 
MM Multiple myeloma 
M-MLV Molony murine leukemia virus 
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MMRF Multiple myeloma research foundation 
MNC Mononuclear cells 
Mo Monocytes 
mRNA Messenger ribonucleic acid 
Neo Neomycin phosphotransferase gene 
NeoR Neomycin resistance 
NGFR Nerve growth factor receptor 
OD Optical density 
P Probability 
PB Peripheral blood 
Pbs Primer binding site 
PBS Phosphate buffered saline solution 
PCMV PCC4-cell-passaged mutant virus 
PCR Polymerase chain reaction 
PE Phycoerythrin 
PI Proliferative index  
PI-PLC Phosphatidylinositol-specific phospholipase C 
PKC Protein kinase C 
PMA Phorbol ester 
Ppt Polypurine tract 
Rb Retinoblastoma 
RE Endoplasmic reticulum 
RNA Ribonucleic acid 
Rpm Revolution per minute 
RT Room temperature 
RT-PCR Reverse transcriptase-polymerase chain reaction 
RZPD Resource Centre of the German Human Genome Project at the Max-
Planck-Institute for Molecular Genetics 
SB Sample buffer 
SCF Stem Cell Factor 
SD Standard deviation  
SDS Sodium dodecyl sulfate 
SEB Staphylococcal enterotoxin B 
Sec Second 
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SFFVp Polycythemic strain of the spleen focus-forming virus 
TAA Tumor-associated antigens 
TAP Transporter associated with antigen presentation 
TGF-b Transforming growth factor-b 
Th T helper cells 
TNF-a Tumor Necrosis Factor-Alpha 
TT Tetanus toxoid 
UV Ultra violet 
V Variable gene segment 
VL Variable region of paraprotein light chain 
VLIgPl Plasmocytoma v riable region of immunoglobulin light chain 
v/v Volume/volume 
w Cleavage attchment site 
X-Gal 5-bromo-4-chloro-3-indolyl-b-D-galactoside 
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6  List of producers 
 
 
-Amersham Pharmacia Biotech, Braunschweig, Germany 
-Amgen, Thousand Oaks, California, USA 
-Applichem GmbH, Darmstadt, Germany 
-ATCC, American Type Culture Collection, Manassas, Virginia, USA 
-Baker Company, Inc., Sanford, Maine, USA 
-B. Braun, Melsungen, Germany 
-Beckmann, Muenchen, Germany 
-Becton Dickinson GmbH, Heidelberg, Germany 
-Bender and Hobein AG, Zurich, Switzerland 
-Biochrom KG, Berlin, Germany 
-Bio-Rad Laboratories GmbH, Muenchen, Germany 
-Calbiochem-Novabiochem GmbH, Schwalbach, Germany 
-Cambridge Technology, Inc., Watertown, Massachusetts, USA  
-CellGenix, Freiburg, Germany 
-Cinna Biotecx Labs Inc., Houston, Texas, USA 
-Clontech GmbH, Heidelberg, Germany 
-CytogenÒ, Lahmer, Germany 
-DAKO, Hamburg, Germany 
-Difco Laboratories, Detroit, USA 
-Eppendorf, Hamburg, Germany 
-Eurogentec, Seraing, Belgium 
-Falcon, New Jersey, USA 
-Gelaire, Meckenheim, Germany 
-Gibco BRL, Neu-Isenburg, Germany 
-Greiner GmbH, Frickenhausen, Germany 
-Hannover medical school (MHH), Hannover, Germany 
-Hawksley & Sons Limited, Sussex, UK 
-Heidolph, Schwabach, Germany 
-Heraeus, Hanau, Germany 
-H. Juergens & Co., Bremen, Germany 
-ICN Biomedicals GmbH, Eschwege, Germany 
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-Immunex Corp, Seattle, Washington, USA 
-Immunotech GmbH, Hamburg, Germany 
-International Biotechnologies Inc, New Haven, Connecticut, USA 
-Invitrogen BV, Groningen, Netherlands 
-Knick, Berlin, Germany 
-Landgraf, Hannover, Germany 
-Leitz, Oberkochen, Germany 
-Life Technologies, Gaithersburg, Maryland, USA 
-LKB, Wallac, UK 
-Macherey-Nagel GmbH, Dueren, Germany 
-MBI Fermentas Molecular Biology GmbH, St. Leon-Rot, Germany 
-Merck KGaA, Darmstadt, Germany 
-Millipore GmbH, Eschborn, Germany 
-Miltenyi Biotec, Bergisch Gladbach, Germany 
-MWG-Biotech, Ebersberg, Germany 
-Nalge Nunc International, Roskilde, D nmark 
-New Brunswick Scientific Co. Inc., Edison, New Jersey, USA 
-New England BioLabs, Beverly, Massachusetts, USA 
-Nikon, Surrey, UK 
-PAA Laboratories GmbH, Coelbe, Germany 
-Pharmacia, Freiburg, Germany 
-PharMingen GmbH, Hamburg, Germany 
-Promega, Mannheim, Germany 
-Qiagen GmbH, Hilden, Germany 
-Roche Diagnostics GmbH, Mannheim, Germany 
-Savant, Farmingdale, New York, USA 
-Seromed, Berlin, Germany 
-Serotec, Oxford, UK 
-Serva, Heidelberg, Germany 
-Shimadzu Deutschland GmbH, Duisburg, Germany 
-Sigma-Aldrich Chemie GmbH, Schnelldorf, Germany  
-Stratagene GmbH, Heidelberg, Germany 
-RZPD, Resource Center of the German Human Genome Project at the Max-Planck-Institute 
for Molecular Genetics, Berlin, Germany 
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-Takara, Otsu, Japan 
-Tebu GmbH, Frankfurt/M., Germany 
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